Sairah Ahmed, M.D.

Peer-Reviewed Articles

1. Strati, P, Brandt, AC, Lionel, A, Henderson, J, Westin, JR, Adkins, S, Shpall, E, Kebriaei, P, Ramdial, JL, Saini, N, Ahmed, S, Flowers, CR, Neelapu, SS, Hildebrandt, MA. Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy. Journal for immunotherapy of cancer 13(10), 2025. e-Pub 2025. PMID: 41067879.
2. Strati, P, Feng, L, Tyshevich, A, Shavronskaya, D, Alesse, JE, English, N, Sheehan, E, Syzrantsev, N, Nesmelov, A, Zhuang, TZ, Chihara, D, Westin, JR, Ahmed, S, Fayad, LE, Henderson, J, Dent, K, McChesney, E, Neelapu, SS, Flowers, CR. A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research 31(19):4079-4088, 2025. e-Pub 2025. PMID: 40729376.
3. Akkad, N, Feng, L, Westin, JR, Hagemeister, FB, Lee, HJ, Fayad, LE, Ahmed, S, Nair, R, Rodriguez, MA, Strati, P, Chihara, D, Flowers, CR, Claret, LC, Ibanez, K, Wang, L, Fowler, N, Henderson, J, Davis, RE, Neelapu, SS, Green, M, Nastoupil, L. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Advances 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
4. Epperla, N, Olszewski, AJ, Ayers, EC, Ahmed, S. Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Hematological Oncology 43(5), 2025. e-Pub 2025. PMID: 40836271.
5. Soto, F, Ebinama, U, Brasher, WP, Harding, WC, Goizueta, AA, Walder, JR, Ewing, A, Shannon, VR, Faiz, S, Altan, M, Shroff, G, Feng, L, Neelapu, SS, Ahmed, S, Nastoupil, L, Sheshadri, A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 25(9):e649-e655, 2025. e-Pub 2025. PMID: 40514309.
6. Corrigan, KL, Berkman, AM, Gunther, J, Andersen, C, Wu, SY, Gibson, A, Cuglievan, B, Garcia, MB, Manzar, G, Fang, PQ, De, BS, Ahmed, S, Nunez, CA, Hildebrandt, MA, McCall, DC, Parsons, SK, Roth, M. Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention 34(9):1483-1491, 2025. e-Pub 2025. PMID: 40488452.
7. Perales, MA, Awan, FT, Boumendil, A, Patel, J, Castagna, L, Angelucci, E, Finel, H, Kulagin, A, Glass, B, Corradini, P, Herrera, AF, Blaise, D, Kharfan-Dabaja, MA, Halahleh, K, Ahmed, S, Martinez, C, Giebel, S, Montoto, S, JONES, RJ, Ahmed, N, Lynch, RC, De Lima, M, Shadman, M, Sauter, C, Ahn, KW, Hamadani, M, Bazarbachi, A, Sureda, A. Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors. Blood 146(8):1011-1029, 2025. e-Pub 2025. PMID: 40623049.
8. Walder, JR, Soto-Lanza, F, Feng, L, Ahmed, S, Neelapu, SS, Ayers, AA, Grosu, HB, Faiz, S, Nastoupil, L, Sheshadri, A. Role of Pulmonary Function Tests to Predict Complications After Chimeric Antigen Receptor T-Cell Therapy. Clinical Lymphoma, Myeloma and Leukemia 25(7):520-526, 2025. e-Pub 2025. PMID: 40000355.
9. Shouval, R, Strouse, CS, Kim, S, Oloyede, T, Ahmed, S, Awan, FT, Luan, D, Bachanova, V, Badar, T, Bar, M, Barba, P, Beitinjaneh, AM, Cashen, A, Dholaria, B, Elsawy, M, Ganguly, S, Geethakumari, PR, Greenbaum, U, Hashmi, H, Hill, LQ, Jain, MD, Jain, T, Kebriaei, P, Kittai, AS, Locke, FL, Lulla, P, Mead, E, McGuirk, J, Mussetti, A, Nishihori, T, Olson, AL, Pennisi, M, Perales, MA, Riedell, PA, Saber, W, Mirza, AS, Magalhaes-Silverman, M, Shpall, E, Sorror, ML, Wudhikarn, K, Turtle, CJ, Moskop, A, Pasquini, MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplantation and Cellular Therapy 31(7):419-433, 2025. e-Pub 2025. PMID: 40288610.
10. Locke, FL, Siddiqi, T, Jacobson, C, Nikiforow, S, Ahmed, S, Miklos, D, Lin, Y, Lunning, M, Hill, BT, Ghobadi, A, Hu, ZH, Hemmer, MT, Zoratti, MJ, Vunnum, S, Tsang, J, Spooner, C, Smith, H, Fu, C, Patel, AR, Miao, H, Shahani, SA, Mirjah, DL, Xu, H, Pasquini, MC. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Advances 9(11):2663-2676, 2025. e-Pub 2025. PMID: 39883946.
11. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma. Nature medicine 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
12. Chihara, D, Steiner, RE, Nair, R, Feng, L, Ahmed, S, Strati, P, Malpica Castillo, LE, Griffith, D, Mathew, SA, Montinez, W, Masand, G, Samaniego, F, Rodriguez, MA, Hagemeister, FB, Fayad, LE, Iyer, SP, Nastoupil, L, Neelapu, SS, Flowers, CR, Westin, JR. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Advances 9(7):1485-1491, 2025. e-Pub 2025. PMID: 39908461.
13. Long, JP, Prakash, R, Edelkamp, P, Knafl, M, Lionel, AC, Nair, R, Ahmed, S, Strati, P, Malpica Castillo, LE, Al Zaki, A, Chien, KS, Chihara, D, Westin, JR, Khawaja, F, Nastoupil, L, Mulanovich, VE, Futreal, A, Woodman, SE, Daver, N, Flowers, CR, Neelapu, SS, Manzano, JM, Iyer, SP. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Network Open 8(4), 2025. e-Pub 2025. PMID: 40193078.
14. Shafat, T, De-La-Rosa-Martinez, D, Khawaja, F, Jiang, Y, Spallone, A, Batista, MV, Ariza Heredia, E, Vilar-Compte, D, Ahmed, S, Becnel, M, Chemaly, RF. Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients With Lymphoma or Multiple Myeloma. Open Forum Infectious Diseases 12(4), 2025. e-Pub 2025. PMID: 40177586.
15. Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
16. Manzar, G, Wu, SY, Dudzinski, SO, Cha, E, Yoder, A, Corrigan, KL, Nasr, L, Sallard, G, Ahmed, S, Fayad, LE, Chihara, D, Nair, R, Westin, JR, Daher, M, Neelapu, SS, Nastoupil, L, Gunther, J, Pinnix, CC, Dabaja, BS, Strati, P, Fang, PQ. Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy. International Journal of Radiation Oncology Biology Physics 121(4):1011-1025, 2025. e-Pub 2025. PMID: 39303997.
17. George, M, Mustafayev, K, Ahmed, S, Thomas, SK, Jiang, Y, Patel, K, Torres, HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma. Hematological Oncology 43(2), 2025. e-Pub 2025. PMID: 39921915.
18. Prasad, R, Rehman, A, Rehman, L, Darbaniyan, F, Blumenberg, V, Schubert, ML, Mor, U, Zamir, E, Schmidt, S, Hayase, T, Chang, C, McDaniel, L, Flores, I, Strati, P, Nair, R, Chihara, D, Fayad, LE, Ahmed, S, Iyer, SP, Wang, ML, Jain, P, Nastoupil, L, Westin, JR, Arora, R, Turner, J, Khawaja, F, Wu, R, Dennison, JB, Menges, M, Hidalgo-Vargas, M, Reid, K, Davila, ML, Dreger, P, Korell, F, Schmitt, A, Tanner, MR, Champlin, RE, Flowers, CR, Shpall, EJ, Hanash, S, Neelapu, SS, Schmitt, M, Subklewe, M, Fahrmann, JF, Thoeringer, C, Elinav, E, Jain, MD, Hayase, E, Jenq, RR, Saini, N. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2025. e-Pub 2025. PMID: 39441941.
19. Manzar, G, Pinnix, CC, Dudzinski, SO, Marqueen, KE, Cha, E, Nasr, L, Yoder, A, Rooney, MK, Strati, P, Ahmed, S, Nze, CC, Nair, R, Fayad, LE, Wang, L, Nastoupil, L, Westin, JR, Flowers, CR, Neelapu, SS, Gunther, J, Dabaja, BS, Wu, SY, Fang, PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39958356.
20. Fang, PQ, Noticewala, SS, Wu, SY, Gunther, J, Ludmir, EB, Medeiros, LJ, Strati, P, Nair, R, Nze, CC, Nastoupil, L, Ahmed, S, Castillo, LM, Fayad, LE, Westin, J, Neelapu, SS, Flowers, CR, Huen, A, Iyer, SP, Dabaja, BS, Pinnix, CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type. Advances in Radiation Oncology 9(12), 2024. e-Pub 2024. PMID: 39553398.
21. Shadman, M, Ahn, KW, Kaur, M, Lekakis, L, Beitinjaneh, AM, Iqbal, M, Ahmed, N, Hill, BT, Hossain, N, Riedell, PA, Gopal, A, Grover, NS, Frigault, M, Brammer, JE, Ghosh, N, Merryman, RW, Lazaryan, A, Ram, R, Hertzberg, M, Savani, BN, Awan, FT, Khimani, F, Ahmed, S, Kenkre, VP, Ulrickson, ML, Shah, N, Kharfan-Dabaja, MA, Herrera, AF, Sauter, C, Hamadani, M. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38977682.
22. Yeh, JC, Pasvolsky, O, Saliba, RM, Figgins, B, Wang, C, Fang, Z, Ahmed, S, Yilmaz, M, Daver, N, Ravandi, F, DiNardo, CD, Short, NJ, Kadia, TM, Al-Atrash, G, Daher, M, Costa, DM, Popat, U, Champlin, R, Shpall, EJ, Oran, B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
23. Herrera, AF, LeBlanc, M, Castellino, SM, Li, H, Rutherford, SC, Evens, AM, Davison, K, Punnett, A, Parsons, SK, Ahmed, S, Casulo, C, Bartlett, NL, Tuscano, JM, Mei, M, Hess, B, Jacobs, RW, Saeed, H, Torka, P, Hu, B, Moskowitz, CH, Kaur, S, Goyal, G, Forlenza, CJ, Doan, A, Lamble, A, Kumar, P, Chowdhury, S, Brinker, B, Sharma, N, Singh, AK, Blum, KA, Perry, AM, Kovach, AE, Hodgson, DC, Constine, LS, Shields, LK, Prica, A, Dillon, H, Little, R, Shipp, MA, Crump, M, Kahl, BS, Leonard, JP, Smith, SM, Song, JY, Kelly, KM, Friedberg, JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. The New England journal of medicine 391(15):1379-1389, 2024. e-Pub 2024. PMID: 39413375.
24. Pinnix, CC, Dabaja, BS, Gunther, J, Fang, PQ, Wu, SY, Nastoupil, L, Strati, P, Nair, R, Ahmed, S, Steiner, RE, Westin, JR, Neelapu, SS, Rodriguez, MA, Lee, HJ, Wang, L, Flowers, CR, Feng, L, Esmaeli, B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma. JAMA Oncology 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
25. Tun, AM, Patel, R, St-Pierre, F, Ouchveridze, E, Niu, A, Thordardottir, T, Obasi, J, Rosenthal, AC, Pophali, PA, Fenske, TS, Karmali, R, Ahmed, S, Johnston, PB. Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma. American journal of hematology 99(9):1712-1720, 2024. e-Pub 2024. PMID: 38837403.
26. George, GC, Andersen, C, Tang, X, Rodriguez, ER, Jafry, MZ, Swartz, MC, Ahmed, S, Barcenas, CH, Livingston, JA, Roth, M, Hildebrandt, MA. Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer. JNCCN Journal of the National Comprehensive Cancer Network 22(6), 2024. e-Pub 2024. PMID: 38996438.
27. Khawaja, F, Ahmed, S, Iyer, S, Sassine, J, Handley, G, Prakash, R, Vanwierren, T, Jackson, J, Zubovskaia, A, Ramdial, JL, Rondon, G, Patel, K, Spallone, A, Ariza Heredia, E, Mulanovich, VE, Angelidakis, G, Jiang, Y, Chemaly, RF. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy. Open Forum Infectious Diseases 11(8), 2024. e-Pub 2024. PMID: 39086466.
28. Rodriguez, ER, Tonn, T, Jafry, MZ, Ahmed, S, Cuglievan, B, Livingston, JA, Flowers, CR, Aune, GJ, Albritton, KH, Roth, M, Xiao, Q, Hildebrandt, MA. Neighborhood-level social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival. JNCI Cancer Spectrum 8(4), 2024. e-Pub 2024. PMID: 39051679.
29. Nze, CC, Andersen, C, Ayers, AA, Westin, JR, Wang, L, Iyer, S, Ahmed, S, Pinnix, CC, Vega Vazquez, F, Nguyen, LH, McNeill, LH, Nastoupil, L, Zhang, K, Bauer, CX, Flowers, CR. Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL. Blood Advances 8(14):3825-3837, 2024. e-Pub 2024. PMID: 38607394.
30. Wagner, R, Natori, A, Prinsloo, S, Otto, AK, Saez-Clarke, E, Ochoa, J, Tworoger, SS, Ulrich, CM, Hathaway, CA, Ahmed, S, McQuade, JL, Peoples, AR, Antoni, MH, Penedo, F, Cohen, L. The role of area deprivation index in health care disruptions among cancer survivors during the SARS-CoV-2 pandemic. Public Health 232:52-60, 2024. e-Pub 2024. PMID: 38735226.
31. Gunther, J, Xu, J, Bhutani, M, Strati, P, Fang, PQ, Wu, SY, Dabaja, BS, Dong, W, Bhosale, PR, Flowers, CR, Nair, R, Malpica Castillo, LE, Fayad, LE, Iyer, S, Parmer, S, Wang, ML, Lee, HJ, Samaniego, F, Westin, JR, Ahmed, S, Nze, CC, Jain, P, Neelapu, SS, Rodriguez, MA, Chihara, D, Nastoupil, L, Pinnix, CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma. The Lancet Haematology 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
32. Locke, FL, Siddiqi, T, Jacobson, C, Ghobadi, A, Ahmed, S, Miklos, D, Perales, MA, Munoz, J, Fingrut, WB, Pennisi, M, Gauthier, J, Shadman, M, Gowda, L, Mirza, AS, Abid, MB, Hong, S, Majhail, NS, Kharfan-Dabaja, MA, Khurana, A, Badar, T, Lin, Y, Bennani-Baiti, N, Herr, M, Hu, ZH, Wang, H, Baer, A, Baro, E, Miao, H, Spooner, C, Xu, H, Pasquini, MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood 143(26):2722-2734, 2024. e-Pub 2024. PMID: 38635762.
33. Jallouk, AP, Kui, N, Sun, R, Westin, JR, Steiner, RE, Nair, R, Nastoupil, L, Fayad, LE, Zaki, AA, Hawkins, MC, Adkins, S, Noorani, M, Das, K, Henderson, J, Shpall, E, Kebriaei, P, Ramdial, JL, Flowers, CR, Neelapu, SS, Ahmed, S, Strati, P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
34. Lunning, M, Wang, Hl, Hu, ZH, Locke, FL, Siddiqi, T, Jacobson, C, Ahmed, S, Miklos, D, Lin, Y, Hill, BT, Ghobadi, A, Neelapu, SS, Westin, JR, Dieyi, C, Field, P, Miao, H, Shahani, SA, Patel, AR, Spooner, C, Fu, C, Muramoto, D, Xu, H, Pasquini, MC. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. American journal of hematology 99(5):880-889, 2024. e-Pub 2024. PMID: 38504387.
35. Moustafa, MA, Ramdial, JL, Tsalatsanis, A, Khimani, F, Dholaria, B, Bojanini, L, Brooks, T, Zain, J, Bennani-Baiti, N, Braunstein, Z, Brammer, JE, Beitinjaneh, AM, Jagadeesh, D, Weng, WK, Kumar, A, Kharfan-Dabaja, MA, Ahmed, S, Murthy, H. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma. Transplantation and Cellular Therapy 30(5):516.e1-516.e10, 2024. e-Pub 2024. PMID: 38431075.
36. Ahmed, S, Bashir, Q, Bassett Jr, R, Ullah, F, Aung, FM, Valdez, B, Alousi, AM, Hosing, C, Kebriaei, P, Khouri, IF, Marin, D, Nieto, Y, Olson, AL, Oran, B, Qazilbash, MH, Rezvani, K, Mehta, RS, Shpall, E, Ciurea, SO, Andersson, BS, Champlin, RE, Popat, UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation. American journal of hematology 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
37. Yalniz, FF, Greenbaum, U, Pasvolsky, O, Milton, D, Kanagal Shamanna, R, Ramdial, JL, Srour, S, Mehta, RS, Alousi, AM, Popat, UR, Nieto, Y, Kebriaei, P, Al-Atrash, G, Oran, B, Hosing, C, Ahmed, S, Champlin, RE, Shpall, E, Qazilbash, MH, Bashir, Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplantation and Cellular Therapy 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
38. Cho, D, Roth, M, Peterson, SK, Jennings, K, Kim, S, Weathers, S, Ahmed, S, Livingston, JA, Barcenas, CH, You, YN, Milbury, K. Associations Between Stress, Health Behaviors, and Quality of Life in Young Couples During the Transition to Survivorship. JMIR Research Protocols 13(1), 2024. e-Pub 2024. PMID: 38652520.
39. Steiner, RE, Hwang, SR, Khurana, A, Habermann, TM, Epperla, N, Annunzio, K, Allen, PB, Baird, K, Paulino, D, Alderuccio, JP, Lossos, IS, David, K, Evens, AM, Pandya, K, Bair, SM, Kamdar, M, Aqeel, SB, Torka, P, Lynch, RC, Smith, SD, Feng, L, Noorani, M, Ahmed, S, Nair, R, Vega Vazquez, F, Wu, SY, Fang, PQ, Pinnix, CC, Gunther, J, Dabaja, BS, Lee, HJ. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Advances 7(24):7485-7493, 2023. e-Pub 2023. PMID: 37603594.
40. Murthy, H, Zhang, MJ, Chen, K, Ahmed, S, Deotare, U, Ganguly, S, Kansagra, AJ, Michelis, FV, Nishihori, T, Patnaik, MM, Abid, MB, Aljurf, M, Arai, Y, Bacher, U, Badar, T, Badawy, SM, Ballen, K, Battiwalla, M, Beitinjaneh, AM, Bejanyan, N, Bhatt, VR, Brown, VI, Martino, R, Cahn, JY, Castillo, P, Cerny, J, Chhabra, S, Copelan, E, Daly, A, Dholaria, B, Perez, MA, Freytes, CO, Grunwald, MR, Hashmi, SK, Hildebrandt, G, Jamy, O, Joseph, JJ, Kanakry, CG, Khera, N, Krem, MM, Kuwatsuka, Y, Lazarus, HM, Lekakis, L, Liu, H, Modi, D, Munshi, P, Mussetti, A, Palmisiano, N, Patel, SS, Rizzieri, D, Seo, S, Shah, MV, Sharma, A, Sohl, M, Solomon, S, Ulrickson, ML, Ustun, C, van der Poel, M, Verdonck, L, Wagner, JL, Wang, TP, Wirk, B, Zeidan, AM, Litzow, M, Kebriaei, P, Hourigan, CS, Weisdorf, DJ, Saber, W, Kharfan-Dabaja, MA. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Advances 7(22):7007-7016, 2023. e-Pub 2023. PMID: 37792849.
41. Strati, P, Jallouk, AP, Deng, Q, Li, X, Feng, L, Sun, R, Adkins, S, Johncy, S, Cain, T, Steiner, RE, Ahmed, S, Chihara, D, Fayad, LE, Iyer, S, Horowitz, S, Nastoupil, L, Nair, R, Hassan, A, Daoud, T, Hawkins, MC, Rodriguez, MA, Shpall, E, Ramdial, JL, Kebriaei, P, Hong, DS, Westin, JR, Neelapu, SS, Green, M. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Advances 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
42. Wu, SY, Fang, PQ, Wang, EB, Ahmed, S, Duvic, M, Jain, P, Castillo, LE, Nair, R, Steiner, RE, Strati, P, Huen, A, Iyer, SP, Pinnix, CC, Dabaja, BS, Gunther, J. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Advances in Radiation Oncology 8(6), 2023. e-Pub 2023. PMID: 37448588.
43. Alkhaldi, H, Reinhardt, A, Barnett, M, Kundu, S, Hosing, C, Ramdial, JL, Saini, N, Srour, S, Alousi, AM, Kebriaei, P, Popat, U, Qazilbash, MH, Champlin, RE, Shpall, E, Gulbis, A, Shigle, TL, Dabaja, BS, Pinnix, CC, Ahmed, S, Steiner, RE, Andersson, BS, Nieto, Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplantation and Cellular Therapy 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
44. Farooq, F, Brandt, JS, Cardonick, E, Polushkina, E, Vose, JM, Ahmed, S, Geethakumari, PR, Olszewski, AJ, Yasin, H, Farooq, U, Hamad, N, Lin, Y, Maggen, C, Fruscio, R, Gziri, MM, Steffensen, KD, Amant, F, Evens, AM. An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy. Blood Advances 7(18):5480-5484, 2023. e-Pub 2023. PMID: 37259563.
45. Strati, P, Li, X, Deng, Q, Marques-Piubelli, ML, Henderson, J, Watson, G, Deaton, FL, Cain, JT, Yang, H, Ravanmehr, V, Fayad, LE, Iyer, SP, Nastoupil, L, Hagemeister, FB, Parra, ER, Saini, N, Takahashi, K, Fowler, N, Westin, JR, Steiner, RE, Nair, R, Flowers, CR, Wang, L, Ahmed, S, Al-Atrash, G, Vega, F, Neelapu, SS, Green, M. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Reports Medicine 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
46. Chiu, CY, Ahmed, S, Thomas, SK, Wang, LS, Mustafayev, K, Fayad, LE, Wierda, WG, Khawaja, F, Torres, HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma, Myeloma and Leukemia 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
47. Hines, MR, Knight, TE, McNerney, KO, Leick, M, Jain, T, Ahmed, S, Frigault, M, Hill, JA, Jain, MD, Johnson, WT, Lin, Y, Mahadeo, KM, Maron, G, Marsh, R, Neelapu, SS, Nikiforow, S, Ombrello, AK, Shah, N, Talleur, A, Turicek, D, Vatsayan, A, Wong, SW, Maus, MV, Komanduri, KV, Berliner, N, Henter, JI, Perales, MA, Frey, NV, Teachey, DT, Frank, MJ, Shah, N. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplantation and Cellular Therapy 29(7):438.e1-438.e16, 2023. e-Pub 2023. PMID: 36906275.
48. Marques-Piubelli, ML, Kim, DH, Medeiros, LJ, Lu, W, Khan, KB, Gomez Bolanos, L, Rodriguez, S, Parra Cuentas, ER, Ok, CY, Aradhya, A, Solis Soto, LM, Nieto, Y, Steiner, RE, Ahmed, S, Vega Vazquez, F. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83(1):143-148, 2023. e-Pub 2023. PMID: 36994939.
49. McKenna, M, Epperla, N, Ghobadi, A, Liu, J, Lazaryan, A, Ibrahim, U, Jacobson, C, Naik, S, Nastoupil, L, Chowdhury, SM, Voorhees, TJ, Jacobs, MT, Farooq, U, Osman, K, Olszewski, AJ, Ahmed, S, Evens, AM. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. British Journal of Haematology 202(2):248-255, 2023. e-Pub 2023. PMID: 37129856.
50. Zeng, K, Huang, M, Lyu, M, Khoury, J, Ahmed, S, Patel, K, Dropulić, B, Reese-Koc, J, Caimi, PF, Sadeghi, T, Lima, Md, Flowers, CR, Parmar, S. Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells 12(14), 2023. e-Pub 2023. PMID: 37508543.
51. Strati, P, Pasvolsky, O, Feng, L, Xu, G, Tewari, SO, Varghese, J, Ow, K, Santiago, M, Al Zaki, A, Jallouk, AP, Neelapu, SS, Kebriaei, P, Shpall, E, Ahmed, S. ASCT vs CART for patients with relapsed LBCL in PR. Blood Advances 7(11):2586-2589, 2023. e-Pub 2023. PMID: 36745104.
52. Wang, XS, Srour, S, Mendoza, TR, Whisenant, M, Subbiah, IM, Gonzalez, E, Jomaa, M, Shen, SE, Cleeland, C, Kebriaei, P, Rezvani, K, Neelapu, SS, Ahmed, S, Shpall, E. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. British Journal of Haematology 201(4):738-746, 2023. e-Pub 2023. PMID: 36733986.
53. Khawaja, F, Srinivasan, K, Spallone, A, Feldman, A, Cantu, S, Ariza Heredia, E, Dvordak, T, Alousi, AM, Ahmed, S, George, MC, Frenzel, E, Bhatti, MM, Chemaly, RF. Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic. American Journal of Infection Control 51(5):506-513, 2023. e-Pub 2023. PMID: 35901993.
54. Thoeringer, C, Saini, N, Zamir, E, Blumenberg, V, Schubert, ML, Mor, U, Fante, MA, Schmidt, S, Hayase, E, Hayase, T, Rohrbach, R, Chang, C, McDaniel, L, Flores, I, Gaiser, R, Edinger, MG, Wolff, D, Heidenreich, M, Strati, P, Nair, R, Chihara, D, Fayad, LE, Ahmed, S, Iyer, SP, Steiner, RE, Jain, P, Nastoupil, L, Westin, JR, Arora, R, Wang, L, Turner, J, Menges, M, Hidalgo-Vargas, M, Reid, K, Dreger, P, Schmitt, A, Müller-Tidow, C, Locke, FL, Davila, ML, Champlin, RE, Flowers, CR, Shpall, E, Poeck, H, Neelapu, SS, Schmitt, M, Subklewe, M, Jain, MD, Jenq, RR, Elinav, E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature medicine 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
55. Afrough, A, Alsfeld, LC, Milton, D, Delgado, R, Popat, UR, Nieto, Y, Kebriaei, P, Oran, B, Saini, N, Srour, S, Hosing, C, Cheema, FH, Ahmed, S, Manasanch, EE, Lee, HC, Kaufman, GP, Patel, K, Weber, DM, Orlowski, R, Pinnix, CC, Dabaja, BS, Thomas, SK, Champlin, RE, Shpall, E, Qazilbash, MH, Bashir, Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
56. Hui, D, Ahmed, S, Nortje, N, George, MC, Andersen, C, Wilson, K, Urbauer, D, Flowers, CR, Bruera, E. Differential Impact of a Multicomponent Goals-of-Care Program in Patients with Hematologic and Solid Malignancies. Cancers 15(5), 2023. e-Pub 2023. PMID: 36900298.
57. Westin, JR, Davis, RE, Feng, L, Hagemeister, FB, Steiner, RE, Lee, HJ, Fayad, LE, Nastoupil, L, Ahmed, S, Rodriguez, A, Fanale, MA, Samaniego, F, Iyer, SP, Nair, R, Oki, Y, Fowler, N, Wang, L, Ma, MJ, Vega Vazquez, F, McDonnell, TJ, Pinnix, CC, Griffith, D, Lu, Y, Tewari, SO, Sun, R, Scott, DW, Flowers, CR, Neelapu, SS, Green, M. Smart Start. Journal of Clinical Oncology 41(4):745-755, 2023. e-Pub 2023. PMID: 35952327.
58. Hui, D, Nortje, N, George, MC, Wilson, K, Urbauer, D, Lenz, CA, Wallace, SK, Andersen, C, Mendoza, TR, Haque, S, Ahmed, S, Delgado Guay, MO, Dalal, S, Rathi, N, Reddy, AS, McQuade, JL, Flowers, CR, Pisters, PW, Aloia, TA, Bruera, E. Impact of an Interdisciplinary Goals-of-Care Program among Medical Inpatients at a Comprehensive Cancer Center during the COVID-19 Pandemic. Journal of Clinical Oncology 41(3):579-589, 2023. e-Pub 2023. PMID: 36201711.
59. Cherng, HJ, Xu, G, Feng, L, Steiner, RE, Fayad, LE, Strati, P, Nair, R, Nastoupil, L, Lee, HJ, Neelapu, SS, Flowers, CR, Rodriguez, MA, Wang, L, Hagemeister, FB, Pinnix, CC, Ramdial, JL, Srour, S, Nieto, Y, Rezvani, K, Champlin, RE, Kebriaei, P, Westin, JR, Macapinlac, HA, Shpall, E, Ahmed, S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. British Journal of Haematology 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
60. Furqan, F, Ahn, KW, Chen, Y, Kaur, M, Abutalib, SA, Ahmed, N, Ahmed, S, Kharfan-Dabaja, MA, Friedberg, JW, Gregory, T, Hill, LQ, Sterling, C, Barta, S, Shadman, M, Perales, MA, Zain, J, Herrera, AF, Sauter, C, Hamadani, M. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. British Journal of Haematology 200(1):54-63, 2023. e-Pub 2023. PMID: 36120837.
61. Zurko, J, Ramdial, JL, Shadman, M, Ahmed, S, Szabo, A, Iovino, L, Tomas, AA, Sauter, C, Perales, MA, Shah, N, Acharya, UH, Jacobson, C, Soiffer, RJ, Wang, TP, Komanduri, KV, Jaglowski, SM, Kittai, AS, Denlinger, N, Iqbal, M, Kharfan-Dabaja, MA, Ayala, E, Chavez, JC, Jain, MD, Locke, FL, Samara, Y, Budde, LE, Mei, M, Pia, AD, Feldman, T, Ahmed, N, Jacobs, R, Ghosh, N, Dholaria, B, Oluwole, OO, Hess, B, Hassan, A, Kenkre, VP, Reagan, P, Awan, FT, Nieto, Y, Hamadani, M, Herrera, AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica 108(1):98-109, 2023. e-Pub 2023. PMID: 35833303.
62. Fahrmann, JF, Saini, N, Chang, C, Irajizad, E, Strati, P, Nair, R, Fayad, LE, Ahmed, S, Lee, HJ, Iyer, SP, Steiner, RE, Vykoukal, JV, Wu, R, Dennison, JB, Nastoupil, L, Jain, P, Wang, L, Green, M, Westin, JR, Blumenberg, V, Davila, ML, Champlin, RE, Shpall, E, Kebriaei, P, Flowers, CR, Jain, MD, Jenq, RR, Thoeringer, C, Subklewe, M, Neelapu, SS, Hanash, S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Reports Medicine 3(11), 2022. e-Pub 2022. PMID: 36384092.
63. Strati, P, Jallouk, AP, Sun, R, Choi, J, Das, K, Cherng, HJ, Ahmed, S, Lee, HJ, Iyer, SP, Nair, R, Nastoupil, L, Steiner, RE, Huff, C, Yu, Y, Mistry, HE, Pulsifer, B, Noorani, M, Saini, N, Shpall, E, Kebriaei, P, Flowers, CR, Westin, JR, Hildebrandt, MA, Neelapu, SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
64. Saliba, RM, Alousi, AM, Pidala, J, Arora, M, Spellman, S, Hemmer, MT, Wang, T, Abboud, CN, Ahmed, S, Antin, JH, Beitinjaneh, AM, Buchbinder, D, Byrne, M, Cahn, JY, Choe, H, Rabi, H, Hematti, P, Kamble, R, Kitko, CL, Laughlin, MJ, Lekakis, L, MacMillan, ML, Martino, R, Mehta, PA, Nishihori, T, Patel, SS, Perales, MA, Rangarajan, HG, Ringden, O, Rosenthal, J, Savani, BN, Schultz, KR, Seo, S, Teshima, T, van der Poel, M, Verdonck, L, Weisdorf, DJ, Wirk, B, Yared, J, Schriber, J, Champlin, RE, Ciurea, SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy 28(10):681-693, 2022. e-Pub 2022. PMID: 35853610.
65. Han, G, Deng, Q, Marques-Piubelli, ML, Dai, E, Dang, M, Ma, MJ, Li, X, Yang, H, Henderson, J, Kudryashova, O, Meerson, M, Isaev, S, Kotlov, N, Nomie, KJ, Bagaev, A, Parra, ER, Solis Soto, LM, Parmar, S, Hagemeister, FB, Ahmed, S, Iyer, SP, Samaniego, F, Steiner, RE, Fayad, LE, Lee, HJ, Fowler, N, Flowers, CR, Strati, P, Westin, JR, Neelapu, SS, Nastoupil, L, Vega, F, Wang, L, Green, M. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood cancer discovery, 2022. PMID: 35687817.
66. Saini, N, Swoboda, DM, Greenbaum, U, Ma, J, Patel, R, Devashish, K, Das, K, Tanner, MR, Strati, P, Nair, R, Fayad, LE, Ahmed, S, Lee, HJ, Iyer, SP, Steiner, RE, Jain, N, Nastoupil, L, Loghavi, S, Tang, G, Bassett Jr, R, Jain, P, Wang, M, Westin, JR, Green, M, Sallman, D, Padron, E, Davila, ML, Locke, FL, Champlin, RE, Garcia-Manero, G, Shpall, E, Kebriaei, P, Flowers, CR, Jain, MD, Wang, F, Futreal, A, Gillis, NK, Neelapu, SS, Takahashi, K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood cancer discovery 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
67. Jacobson, C, Locke, FL, Ma, L, Asubonteng, J, Hu, ZH, Siddiqi, T, Ahmed, S, Ghobadi, A, Miklos, D, Lin, Y, Perales, MA, Lunning, M, Herr, M, Hill, BT, Ganguly, S, Dong, H, Nikiforow, S, Hooper, M, Kawashima, J, Xu, H, Pasquini, MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplantation and Cellular Therapy 28(9):581.e1-581.e8, 2022. e-Pub 2022. PMID: 35609867.
68. Cherng, HJ, Sun, R, Sugg, B, Irwin, R, Yang, H, Le, CC, Deng, Q, Fayad, LE, Fowler, N, Parmar, S, Steiner, RE, Hagemeister, FB, Nair, R, Lee, HJ, Rodriguez, MA, Samaniego, F, Iyer, SP, Flowers, CR, Wang, L, Nastoupil, L, Neelapu, SS, Ahmed, S, Strati, P, Green, M, Westin, JR. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
69. Andersson, BS, Thall, PF, Ma, J, Valdez, B, Bassett Jr, R, Chen, J, Ahmed, S, Alousi, AM, Bashir, Q, Ciurea, SO, Gulbis, A, Cool, R, Kawedia, J, Hosing, C, Kebriaei, P, Kornblau, SM, Myers, AL, Oran, B, Rezvani, K, Shah, ND, Shpall, E, Parmar, S, Popat, UR, Nieto, Y, Champlin, RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone marrow transplantation 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
70. Hamid, MS, Rutherford, SC, Jang, H, Kim, S, Patel, K, Bartlett, NL, Malecek, M, Watkins, MP, Maddocks, K, Bond, D, Feldman, T, Magarelli, G, Advani, RH, Spinner, MA, Evens, AM, Shah, M, Ahmed, S, Stephens, DM, Allen, P, Tees, MT, Karmali, R, Cheson, B, Yazdy, M, Strouse, CS, Bailey, NA, Pagel, JM, Ramchandren, R. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan. Clinical Lymphoma, Myeloma and Leukemia 22(7):e435-e442, 2022. e-Pub 2022. PMID: 35093285.
71. Al Zaki, A, Feng, L, Watson, G, Ahmed, S, Mistry, HE, Nastoupil, L, Hawkins, MC, Nair, R, Iyer, SP, Lee, HJ, Steiner, RE, Flowers, CR, Shpall, E, Kebriaei, P, Neelapu, SS, Westin, JR, Strati, P. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Advances 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
72. Akin, S, Hosing, C, Khouri, IF, Ahmed, S, Alousi, AM, Fowler, N, Joseph, JJ, Truxillo, J, Ramdial, JL, Maadani, F, Rondon, G, Daher, M, Im, JS, Steiner, RE, Westin, JR, Iyer, SP, Dabaja, BS, Anderlini, P, Popat, UR, Qazilbash, MH, Flowers, CR, Shpall, E, Champlin, RE, Nieto, Y, Srour, S. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Advances 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
73. Nieto, Y, Gruschkus, SK, Valdez, B, Jones, R, Anderlini, P, Hosing, C, Popat, UR, Qazilbash, MH, Kebriaei, P, Alousi, AM, Saini, N, Srour, S, Rezvani, K, Ramdial, JL, Barnett, M, Gulbis, A, Shigle, TL, Ahmed, S, Iyer, SP, Lee, H, Nair, R, Parmar, S, Steiner, RE, Dabaja, BS, Pinnix, CC, Gunther, J, Cuglievan, B, Mahadeo, KM, Khazal, SJ, Chuang, HH, Champlin, RE, Shpall, E, Andersson, BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
74. Savani, M, Ahn, KW, Chen, Y, Ahmed, S, Cashen, A, Shadman, M, Modi, D, Khimani, F, Cutler, C, Zain, J, Brammer, JE, Rezvani, A, Fenske, TS, Sauter, C, Kharfan-Dabaja, MA, Herrera, AF, Hamadani, M. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. British Journal of Haematology 197(2):212-222, 2022. e-Pub 2022. PMID: 35106754.
75. Ahmed, S, Zhao, Q, Hanel, W, Qazilbash, MH, Patel, K, Narra, R, Kansagra, AJ, Iqbal, M, Awan, FT, Christian, B, Jaglowski, SM, Kharfan-Dabaja, MA, Hamadani, M, Epperla, N. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological Oncology 40(1):48-56, 2022. e-Pub 2022. PMID: 34763367.
76. Hamadani, M, Gopal, A, Pasquini, MC, Kim, S, Qiu, X, Ahmed, S, Lazaryan, A, Bhatt, VR, Daly, A, Lulla, P, Ciurea, SO, Gauthier, J, Agrawal, V, Grover, NS, Lekakis, L, Modi, D, Dahi, PB, Herr, M, Johnson, PC, Hashmi, H, Hematti, P, Locke, FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL. Blood Advances 6(2):486-494, 2022. e-Pub 2022. PMID: 34673903.
77. Bashir, Q, Milton, D, Popat, UR, Kebriaei, P, Hosing, C, Khouri, IF, Rezvani, K, Nieto, Y, Oran, B, Srour, S, Saini, N, Olson, AL, Ahmed, S, Al-Atrash, G, Rondon, G, Konopleva, M, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone marrow transplantation 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
78. Whisenant, M, Srour, S, Williams, LA, Subbiah, IM, Griffin, D, Ponce, D, Kebriaei, P, Neelapu, SS, Shpall, E, Ahmed, S, Wang, XS. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Seminars in oncology nursing 37(6), 2021. e-Pub 2021. PMID: 34629213.
79. Zhao, H, Duan, Z, Li, M, Chiao, EY, Ahmed, S, Shih, YT, Hwang, JP. Increased Incidence of Human Papillomavirus-Related Precancer or Second Malignancy Among Allogeneic Stem Cell Transplantation Patients. Transplantation and Cellular Therapy 27(12):1016.e1-1016.e9, 2021. e-Pub 2021. PMID: 34474166.
80. Berkman, AM, Andersen, C, Puthenpura, V, Livingston, JA, Ahmed, S, Cuglievan, B, Hildebrandt, MA, Roth, M. Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. Cancer Epidemiology 75, 2021. e-Pub 2021. PMID: 34597882.
81. Munshi, P, Hamadani, M, Kumar, A, Dreger, P, Friedberg, JW, Dreyling, M, Kahl, BS, Jerkeman, M, Kharfan-Dabaja, MA, Locke, FL, Shadman, M, Hill, BT, Ahmed, S, Herrera, AF, Sauter, C, Bachanova, V, Ghosh, N, Lunning, M, Kenkre, VP, Aljurf, M, Wang, L, Maddocks, K, Leonard, JP, Kamdar, M, Phillips, T, Cashen, A, Inwards, DJ, Sureda, A, Cohen, JB, Smith, SM, Carlo-Stella, C, Savani, BN, Robinson, S, Fenske, TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone marrow transplantation 56(12):2911-2921, 2021. e-Pub 2021. PMID: 34413469.
82. Zhang, S, Jiang, C, Han, G, Hao, D, Lian, J, Liu, Y, Zhang, RJ, McIntosh, J, Wang, R, Dang, M, Dai, E, Wang, Y, Santos, DA, Badillo, M, Leeming, A, Chen, Z, Hartig, K, Bigcal, J, Zhou, J, Kanagal Shamanna, R, Ok, CY, Lee, H, Steiner, RE, Zhang, J, Song, X, Nair, R, Ahmed, S, Rodriquez, A, Thirumurthi, S, Jain, P, Wagner-Bartak, N, Hill, H, Nomie, K, Flowers, CR, Futreal, A, Wang, L, Wang, L. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34001881.
83. Wang, XS, Srour, S, Whisenant, M, Subbiah, IM, Chen, TH, Ponce, D, Gonzalez, AG, Jomaa, M, Mendoza, TR, Cleland, CS, Kebriaei, P, Neelapu, SS, Rezvani, K, Ahmed, S, Shpall, E. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplantation and Cellular Therapy 27(11):930.e1-930.e10, 2021. e-Pub 2021. PMID: 34265479.
84. Al Feghali, KA, Fang, PQ, Gule-Monroe, MK, Milgrom, SA, Khoury, J, Gunther, J, Sheu, T, Nair, R, Ahmed, S, Steiner, RE, Strati, P, Shpall, E, Nieto, Y, Hosing, C, Nastoupil, L, Westin, JR, Neelapu, SS, Fowler, N, Flowers, CR, Pinnix, CC, Dabaja, BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leukemia and Lymphoma 62(10):2400-2407, 2021. PMID: 33942701.
85. Strati, P, Varma, A, Adkins, S, Nastoupil, L, Westin, JR, Hagemeister, FB, Fowler, N, Lee, HJ, Fayad, LE, Samaniego, F, Ahmed, S, Chen, Y, Horowitz, S, Arafat, S, Johncy, S, Kebriaei, P, Mulanovich, VE, Ariza Heredia, E, Neelapu, SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
86. Epperla, N, Ahn, KW, Khanal, M, Litovich, C, Ahmed, S, Ghosh, N, Fenske, TS, Kharfan-Dabaja, MA, Sureda, A, Hamadani, M. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplantation and Cellular Therapy 27(1):58-66, 2021. e-Pub 2021. PMID: 32956819.
87. Munshi, P, Hamadani, M, Kumar, A, Dreger, P, Friedberg, JW, Dreyling, M, Kahl, BS, Jerkeman, M, Kharfan-Dabaja, MA, Locke, FL, Shadman, M, Hill, BT, Ahmed, S, Herrera, AF, Sauter, C, Bachanova, V, Ghosh, N, Lunning, M, Kenkre, VP, Aljurf, M, Wang, L, Maddocks, K, Leonard, JP, Kamdar, M, Phillips, T, Cashen, A, Inwards, DJ, Sureda, A, Cohen, JB, Smith, SM, Carlo-Stella, C, Savani, BN, Robinson, S, Fenske, TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy 27(9):720-728, 2021. e-Pub 2021. PMID: 34452722.
88. Berkman, AM, Andersen, C, Puthenpura, V, Livingston, JA, Ahmed, S, Cuglievan, B, Hildebrandt, MA, Roth, M. Impact of race, ethnicity, and socioeconomic status over time on the long-term survival of adolescent and young adult hodgkin lymphoma survivors. Cancer Epidemiology Biomarkers and Prevention 30(9):1717-1725, 2021. e-Pub 2021. PMID: 34244160.
89. Greenbaum, U, Strati, P, Saliba, RM, Torres, J, Rondon, G, Nieto, Y, Hosing, C, Srour, S, Westin, JR, Fayad, LE, Lee, HJ, Iyer, SP, Nair, R, Nastoupil, L, Parmar, S, Rodriguez, MA, Samaniego, F, Steiner, RE, Wang, L, Pinnix, CC, Flowers, CR, Tummala, S, Ramdial, JL, Yalniz, FF, Hawkins, MC, Rezvani, K, Champlin, RE, Shpall, E, Neelapu, SS, Kebriaei, P, Ahmed, S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Advances 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
90. Scordo, M, Wang, TP, Ahn, KW, Chen, Y, Ahmed, S, Awan, FT, Beitinjaneh, AM, Chen, A, Chow, VA, Dholaria, B, Epperla, N, Farooq, U, Ghosh, N, Grover, NS, Hamad, N, Hildebrandt, G, Holmberg, L, Hong, S, Inwards, DJ, Jimenez, A, Karmali, R, Kenkre, VP, Khimani, F, Klyuchnikov, E, Krem, MM, Munshi, P, Nieto, Y, Prestidge, TD, Geethakumari, PR, Rezvani, A, Riedell, PA, Seo, S, Shah, N, Solh, MM, Yared, J, Kharfan-Dabaja, MA, Herrera, AF, Hamadani, M, Sauter, C. Outcomes Associated with Thiotepa-Based Conditioning in Patients with Primary Central Nervous System Lymphoma after Autologous Hematopoietic Cell Transplant. JAMA Oncology 7(7):993-1003, 2021. e-Pub 2021. PMID: 33956047.
91. Strati, P, Ahmed, S, Furqan, F, Fayad, LE, Lee, HJ, Iyer, SP, Nair, R, Nastoupil, L, Parmar, S, Rodriguez, MA, Samaniego, F, Steiner, RE, Wang, L, Pinnix, CC, Horowitz, S, Feng, L, Sun, R, Claussen, C, Hawkins, MC, Johnson, NA, Singh, P, Mistry, HE, Johncy, S, Adkins, S, Kebriaei, P, Shpall, E, Green, M, Flowers, CR, Westin, JR, Neelapu, SS. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
92. Joseph, JJ, Ma, J, Hennawy, F, Abdulrazzaq, M, Saini, N, Patel, R, Hosing, C, Alousi, AM, Anderlini, P, Popat, UR, Qazilbash, MH, Shpall, E, Srour, S, Kebriaei, P, Bashir, Q, Nastoupil, L, Westin, JR, Rondon, G, Champlin, RE, Andersson, BS, Nieto, Y, Muzzafar, T, Ahmed, S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
93. Ahmed, S, Bashir, Q, Bassett Jr, R, Poon, MC, Valdez, B, Konoplev, SN, Alousi, AM, Andersson, BS, Ciurea, SO, Hosing, C, Jones, R, Kebriaei, P, Khouri, IF, Kim, S, Nieto, Y, Olson, AL, Oran, B, Parmar, S, Qazilbash, MH, Rezvani, K, Shah, ND, Shpall, E, Champlin, RE, Popat, UR. Eltrombopag for Post-Transplantation Thrombocytopenia. Transplantation and Cellular Therapy 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
94. Fang, PQ, Gunther, J, Pinnix, CC, Dong, W, Strati, P, Nastoupil, L, Steiner, RE, Ahmed, S, Damron, EP, Fowler, N, Nair, R, Westin, JR, Neelapu, SS, Ha, CS, Dabaja, BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. International Journal of Radiation Oncology Biology Physics 109(5):1414-1420, 2021. e-Pub 2021. PMID: 33309978.
95. Srour, S, Saliba, RM, Bashir, Q, Popat, UR, Ahmed, S, Mehta, RS, Delgado, R, Rondon, G, Parmar, S, Kebriaei, P, Hosing, C, Manasanch, EE, Lee, HC, Patel, K, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Nieto, Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
96. Strati, P, Cheng, PT, Steiner, RE, Alcedo Andrade, PE, Feng, L, Sano, D, Rao, VA, Singh, P, Miranda, R, Gunther, J, Pinnix, CC, Dabaja, BS, Cuglievan, B, Xing, K, Villa, D, Skinnider, BF, Sehn, L, Connors, JM, Nieto, Y, Ahmed, S, Lee, HJ, Savage, KJ. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma. British Journal of Haematology 192(3):560-567, 2021. e-Pub 2021. PMID: 33517581.
97. Augustyn, A, Medeiros, LJ, Ludmir, EB, Gunther, J, Fang, PQ, Li, S, Ok, CY, Bankston, ME, Verma, V, Pasalic, D, Ahmed, S, Nastoupil, L, Westin, JR, Strati, P, Neelapu, SS, Nair, R, Steiner, RE, Iyer, SP, Rodriguez, MA, Fayad, LE, Flowers, CR, Dabaja, BS, Pinnix, CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leukemia and Lymphoma 62(6):1361-1369, 2021. e-Pub 2021. PMID: 33480830.
98. Olson, AL, Saliba, RM, Oran, B, Chen, J, Alousi, AM, Ahmed, S, Bashir, Q, Ciurea, SO, Hosing, C, Im, JS, Kebriaei, P, Khouri, IF, Mehta, RS, Nieto, Y, Parmar, S, Rezvani, K, Shah, ND, Shpall, E, Srour, S, Qazilbash, MH, Andersson, BS, Champlin, RE, Popat, UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta haematologica 144(1):74-81, 2021. e-Pub 2021. PMID: 32604096.
99. Torres, HA, Lok, AS, Suarez-Almazor, M, Warneke, C, Kaseb, A, Miller, E, Sturgis, EM, Foreman, J, Angelidakis, G, Ahmed, S, Ferrajoli, A, Samaniego, F, Hawk, E, Hwang, JP. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy. Supportive Care in Cancer 29(1):97-105, 2021. e-Pub 2021. PMID: 32314052.
100. Pinnix, CC, Gunther, J, Fang, PQ, Bankston, ME, Milgrom, SA, Boyce, D, Lee, HJ, Nair, R, Steiner, RE, Strati, P, Ahmed, S, Iyer, SP, Westin, JR, Parmar, S, Rodriguez, MA, Nastoupil, L, Neelapu, SS, Flowers, CR, Dabaja, BS. Assessment of Radiation Doses Delivered to Organs at Risk among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy. JAMA Network Open 3(9):E2013935, 2020. e-Pub 2020. PMID: 32990738.
101. Strati, P, Nastoupil, L, Westin, JR, Fayad, LE, Ahmed, S, Fowler, N, Hagemeister, FB, Lee, HJ, Iyer, SP, Nair, R, Parmar, S, Rodriguez, MA, Samaniego, F, Steiner, RE, Wang, L, Pinnix, CC, Adkins, S, Claussen, C, Martinez, C, Hawkins, MC, Johnson, NA, Singh, P, Mistry, HE, Horowitz, S, George, S, Feng, L, Kebriaei, P, Shpall, E, Neelapu, SS, Tummala, S, Chi, TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances 4(16):3943-3951, 2020. e-Pub 2020. PMID: 32822484.
102. Glober, G, Gunther, J, Fang, PQ, Milgrom, SA, Rao Korivi, B, Jensen, CT, Wagner-Bartak, N, Ahmed, S, Lee, HJ, Nair, R, Steiner, RE, Parmar, S, Iyer, SP, Westin, JR, Fayad, LE, Rodriguez, MA, Neelapu, SS, Nastoupil, L, Flowers, CR, Dabaja, BS, Pinnix, CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission. Clinical Lymphoma, Myeloma and Leukemia 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
103. Ahmed, S, Ghosh, N, Ahn, KW, Khanal, M, Litovich, C, Mussetti, A, Chhabra, S, Cairo, MS, Mei, M, William, BM, Nathan, S, Bejanyan, N, Olsson, R, Dahi, PB, van der Poel, M, Steinberg, A, Kanakry, JA, Cerny, J, Farooq, U, Seo, S, Kharfan-Dabaja, MA, Sureda, A, Fenske, TS, Hamadani, M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. British Journal of Haematology 190(4):573-582, 2020. e-Pub 2020. PMID: 32314807.
104. Pinnix, CC, Gunther, J, Dabaja, BS, Strati, P, Fang, PQ, Hawkins, MC, Adkins, S, Westin, JR, Ahmed, S, Fayad, LE, Lee, HJ, Nair, R, Steiner, RE, Iyer, SP, Rodriguez, MA, Wang, L, Flowers, CR, Neelapu, SS, Nastoupil, L. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances 4(13):2871-2883, 2020. e-Pub 2020. PMID: 32589728.
105. Ghosh, N, Ahmed, S, Ahn, KW, Khanal, M, Litovich, C, Aljurf, M, Bacher, VU, Bredeson, C, Epperla, N, Farhadfar, N, Freytes, CO, Ganguly, S, Haverkos, B, Inwards, DJ, Kamble, R, Lazarus, HM, Lekakis, L, Murthy, H, Nishihori, T, Geethakumari, PR, Rizzieri, D, Yared, J, Kharfan-Dabaja, MA, Sureda, A, Hamadani, M. Association of Reduced-Intensity Conditioning Regimens with Overall Survival among Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncology 6(7):1011-1018, 2020. e-Pub 2020. PMID: 32496525.
106. Zhao, S, Kanagal Shamanna, R, Navsaria, L, Ok, CY, Zhang, S, Nomie, K, Han, G, Hao, D, Hill, HA, Jiang, C, Yao, Y, Nastoupil, L, Westin, JR, Fayad, LE, Nair, R, Steiner, RE, Ahmed, S, Samaniego, F, Iyer, SP, Oriabure, O, Chen, W, Song, X, Zhang, J, Badillo, M, Moghrabi, O, Aranda, J, Tang, G, Yin, CC, Patel, KP, Medeiros, LJ, Li, S, Vega Vazquez, F, Thirumurthi, S, Xu, G, Neelapu, SS, Flowers, CR, Romaguera, JE, Fowler, N, Wang, L, Wang, L, Jain, P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. American journal of hematology 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
107. Yalniz, FF, Patel, KP, Bashir, Q, Marin, D, Ahmed, S, Alousi, AM, Chen, J, Ciurea, SO, Rezvani, K, Popat, UR, Shpall, E, Champlin, RE, Oran, B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
108. Jagadeesh, D, Majhail, NS, He, Y, Ahn, KW, Litovich, C, Ahmed, S, Aljurf, M, Bacher, U, Badawy, SM, Bejanyan, N, Cairo, MS, Cerny, J, Epperla, N, Farhadfar, N, Freytes, CO, Gale, RP, Haverkos, B, Hossain, N, Inwards, DJ, Kamble, R, Kenkre, VP, Lazarus, HM, Lazaryan, A, Lekakis, L, Mei, M, Murthy, H, Mussetti, A, Nathan, S, Nishihori, T, Olsson, R, Geethakumari, PR, Savani, BN, Yared, J, Fenske, TS, Kharfan-Dabaja, MA, Sureda, A, Hamadani, M. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer 126(10):2279-2287, 2020. e-Pub 2020. PMID: 32049359.
109. Strati, P, Ahmed, MA, Nastoupil, L, Feng, L, Hagemeister, FB, Fayad, LE, Rodriguez, MA, Samaniego, F, Wang, L, Westin, JR, Lee, HJ, Iyer, SP, Parmar, S, Ahmed, S, Nair, R, Steiner, RE, Noorani, M, Flowers, CR, Davis, RE, Fowler, N, Neelapu, SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia and Lymphoma 61(6):1380-1387, 2020. e-Pub 2020. PMID: 31971032.
110. Varma, A, Abraham, S, Mehta, RS, Saini, N, Honhar, M, Rashid, M, Chen, J, Srour, S, Bashir, Q, Rondon, G, Oran, B, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Marin, D, Khouri, IF, Ciurea, SO, Qazilbash, MH, Rezvani, K, Anderlini, P, Andersson, BS, Shpall, E, Champlin, RE, Popat, UR. Idiopathic refractory ascites after allogeneic stem cell transplantation. Blood Advances 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
111. Varma, A, Sui, D, Milton, D, Tang, G, Saini, N, Hasan, O, Mukherjee, A, Joseph, JJ, Bashir, Q, Rondon, G, Srour, S, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Mehta, RS, Khouri, IF, Ahmed, H, Iyer, SP, Weber, DM, Thomas, SK, Manasanch, EE, Lee, HC, Patel, K, Ciurea, SO, Shpall, E, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
112. Jain, P, Zhang, S, Kanagal Shamanna, R, Ok, CY, Nomie, K, Gonzalez, GN, Gonzalez-Pagan, O, Hill, HA, Lee, HJ, Fayad, LE, Westin, JR, Nastoupil, L, Hagemeister, FB, Chen, W, Oriabure, O, Badillo, M, Jiang, C, Yao, Y, Li, S, Tang, G, Yin, CC, Patel, KP, Medeiros, LJ, Nair, R, Ahmed, S, Iyer, SP, Thirumurthi, S, Champlin, RE, Xu, G, Pan, T, Santos, DA, Wang, R, Han, G, Zhang, J, Song, X, Neelapu, SS, Romaguera, JE, Futreal, A, Flowers, CR, Fowler, N, Wang, L, Wang, L. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
113. Badar, T, Epperla, N, Szabo, A, Borson, S, Vaughn, J, George, G, Saini, N, Shah, AR, Patel, R, Ahmed, S, Shah, N, Cashen, A, Hamadani, M, Fenske, TS. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances 4(1):41-54, 2020. e-Pub 2020. PMID: 31899797.
114. Bashir, Q, Chamoun, K, Milton, D, Khan, M, Ahmed, S, Mehta, RS, Popat, UR, Kebriaei, P, Nieto, Y, Oran, B, Ciurea, SO, Hosing, C, Khouri, IF, Patel, K, Manasanch, EE, Lee, HC, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leukemia and Lymphoma 60(14):3536-3543, 2019. e-Pub 2019. PMID: 31282244.
115. Saini, N, Ma, J, Milton, D, Patel, R, Varma, A, Bashir, Q, Delgado, R, Mukherjee, A, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Tang, G, Mehta, RS, Srour, S, Khouri, IF, Iyer, SP, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Patel, K, Orlowski, R, Champlin, RE, Qazilbash, MH. Impact of autologous transplantation in patients with multiple myeloma with t(11;14). Clinical Cancer Research 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
116. Tabchi, S, Nair, R, Kunacheewa, C, Patel, K, Lee, HC, Thomas, SK, Amini, B, Ahmed, S, Mehta, RS, Bashir, Q, Qazilbash, MH, Weber, DM, Orlowski, R, Alexanian, R, Feng, L, Manasanch, EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
117. Ahmed, S, Kanakry, JA, Ahn, KW, Litovich, C, Abdel-Azim, H, Aljurf, M, Bacher, VU, Bejanyan, N, Cohen, JB, Farooq, U, Fuchs, E, Bolaños-Meade, J, Ghosh, N, Herrera, AF, Hossain, N, Inwards, DJ, Kanate, AS, Martino, R, Munshi, P, Murthy, H, Mussetti, A, Nieto, Y, Perales, MA, Romee, R, Savani, BN, Seo, S, Wirk, B, Yared, J, Sureda, A, Fenske, TS, Hamadani, M. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 25(9):1859-1868, 2019. e-Pub 2019. PMID: 31132455.
118. Doan, V, Yeh, JC, Gulbis, A, Aitken, SL, Ariza Heredia, E, Ahmed, S. Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 25(8):1637-1641, 2019. e-Pub 2019. PMID: 31002991.
119. Epperla, N, Badar, T, Szabo, A, Vaughn, J, Borson, S, Saini, N, Patel, R, Shah, N, Hamadani, M, Ahmed, S, Cashen, A, Fenske, TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Advances 3(11):1661-1669, 2019. e-Pub 2019. PMID: 31167818.
120. Epperla, N, Ahn, KW, Litovich, C, Ahmed, S, Battiwalla, M, Cohen, JB, Dahi, PB, Farhadfar, N, Farooq, U, Freytes, CO, Ghosh, N, Haverkos, B, Herrera, AF, Hertzberg, M, Hildebrandt, G, Inwards, DJ, Kharfan-Dabaja, MA, Khimani, F, Lazarus, HM, Lazaryan, A, Lekakis, L, Murthy, H, Nathan, S, Nishihori, T, Pawarode, A, Prestidge, TD, Geethakumari, PR, Rezvani, A, Romee, R, Shah, N, Sureda, A, Fenske, TS, Hamadani, M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma. Journal of Hematology and Oncology 12(1), 2019. e-Pub 2019. PMID: 30630534.
121. Yoder, AK, Gunther, J, Milgrom, SA, Mirkovic, D, Nastoupil, L, Neelapu, SS, Fanale, MA, Fowler, N, Westin, JR, Lee, HJ, Rodriguez, MA, Iyer, SP, Fayad, LE, Nieto, Y, Hosing, C, Ahmed, S, Medeiros, LJ, Khoury, J, Garg, N, Amini, B, Dabaja, BS, Pinnix, CC. Hitting a Moving Target. Clinical Lymphoma, Myeloma and Leukemia 19(1):e51-e61, 2019. e-Pub 2019. PMID: 30360985.
122. Popat, UR, Mehta, RS, Bassett Jr, R, Chen, J, Valdez, B, Kawedia, J, Ahmed, S, Alousi, AM, Anderlini, P, Al-Atrash, G, Bashir, Q, Ciurea, SO, Hosing, C, Im, JS, Jones, R, Kebriaei, P, Khouri, IF, Marin, D, Nieto, Y, Olson, AL, Oran, B, Parmar, S, Rezvani, K, Qazilbash, MH, Shah, ND, Srour, S, Shpall, E, Champlin, RE, Andersson, BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities. The Lancet Haematology 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
123. Kellner, JN, Delemarre, EM, Yvon, E, Nierkens, S, Boelens, JJ, McNiece, I, Olson, AL, Nieto, Y, Ciurea, SO, Popat, UR, Ahmed, S, Champlin, RE, Ramos, J, Nishimoto, M, Ma, H, Zeng, K, Thall, PF, Khoury, J, Negrin, R, Andersson, BS, Parmar, S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation. Oncotarget 9(86):35611-35622, 2018. e-Pub 2018. PMID: 30479692.
124. Muftuoglu, M, Olson, AL, Marin, D, Ahmed, S, Mulanovich, VE, Tummala, S, Chi, TL, Ferrajoli, A, Kaur, I, Li, L, Champlin, RE, Shpall, E, Rezvani, K. Allogeneic BK virus-specific t cells for progressive multifocal leukoencephalopathy. New England Journal of Medicine 379(15):1443-1451, 2018. e-Pub 2018. PMID: 30304652.
125. Sheu, T, Milgrom, SA, Andraos, TY, Gunther, J, Chi, TL, Nastoupil, L, Fowler, N, Oki, Y, Fanale, MA, Fayad, LE, Hagemeister, FB, Neelapu, SS, Medeiros, LJ, Hosing, C, Nieto, Y, Ahmed, S, Alousi, AM, Dabaja, BS, Pinnix, CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Advances in Radiation Oncology 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
126. Lu, H, Lok, AS, Warneke, C, Ahmed, S, Torres, HA, Martinez, F, Suarez-Almazor, M, Foreman, J, Ferrajoli, A, Hwang, JP. Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer. The Lancet Haematology 5(10):e474-e478, 2018. e-Pub 2018. PMID: 30290904.
127. Nieto, Y, Thall, PF, Ma, J, Valdez, B, Ahmed, S, Anderlini, P, Popat, UR, Jones, R, Shpall, E, Hosing, C, Qazilbash, MH, Kebriaei, P, Alousi, AM, Timmons, M, Gulbis, A, Myers, AL, Oki, Y, Fanale, MA, Dabaja, BS, Pinnix, CC, Milgrom, SA, Champlin, RE, Andersson, BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
128. Smith, SM, Godfrey, J, Ahn, KW, Digilio, A, Ahmed, S, Agrawal, V, Bachanova, V, Bacher, U, Bashey, A, Bolaños-Meade, J, Cairo, MS, Chen, A, Chhabra, S, Copelan, E, Dahi, PB, Aljurf, M, Farooq, U, Ganguly, S, Hertzberg, M, Holmberg, L, Inwards, DJ, Kanate, AS, Karmali, R, Kenkre, VP, Kharfan-Dabaja, MA, Klein, A, Lazarus, HM, Mei, M, Mussetti, A, Nishihori, T, Geethakumari, PR, Saad, AA, Savani, BN, Schouten, HC, Shah, N, Urbano-Ispizua, A, Vij, R, Vose, JM, Sureda, A, Hamadani, M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer 124(12):2541-2551, 2018. e-Pub 2018. PMID: 29645093.
129. Ciurea, SO, Shah, MV, Saliba, RM, Gaballa, S, Kongtim, P, Rondon, G, Chen, J, Wallis, W, Cao, K, Konopleva, M, Daver, N, Cortes, JE, Ravandi-Kashani, F, Alousi, AM, Ahmed, S, Popat, UR, Parmar, S, Bashir, Q, Oran, B, Hosing, C, Shpall, E, Rezvani, K, Khouri, IF, Kebriaei, P, Champlin, RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
130. Casulo, C, Friedberg, JW, Ahn, KW, Flowers, CR, Digilio, A, Smith, SM, Ahmed, S, Inwards, DJ, Aljurf, M, Chen, A, Choe, H, Cohen, JB, Copelan, E, Farooq, U, Fenske, TS, Freytes, CO, Gaballa, S, Ganguly, S, Jethava, Y, Kamble, R, Kenkre, VP, Lazarus, HM, Lazaryan, A, Olsson, R, Rezvani, A, Rizzieri, D, Seo, S, Shah, GL, Shah, ND, Solh, MM, Sureda, A, William, BM, Cumpston, A, Zelenetz, AD, Link, BK, Hamadani, M. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure. Biology of Blood and Marrow Transplantation 24(6):1163-1171, 2018. e-Pub 2018. PMID: 29242111.
131. Chahoud, J, Sui, D, Erwin, WD, Gulbis, A, Korbling, M, Zhang, M, Ahmed, S, Al-Atrash, G, Anderlini, P, Ciurea, SO, Oran, B, Fayad, LE, Bassett Jr, R, Jabbour, EJ, Medeiros, LJ, Macapinlac, HA, Young, KH, Khouri, IF. Updated results of rituximab pre- and post-beam with or without90Yttrium ibritumomab tiuxetan during autologous transplant for diffuse large b-cell lymphoma. Clinical Cancer Research 24(10):2304-2311, 2018. e-Pub 2018. PMID: 29476021.
132. Hwang, JP, Ahmed, S, Ariza Heredia, E, Duan, Z, Zhao, H, Schmeler, KM, Ramondetta, LM, Parker, SL, Suarez-Almazor, M, Ferrajoli, A, Shih, YT, Giordano, SH, Chiao, EY. Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biology of Blood and Marrow Transplantation 24(5):1094-1098, 2018. e-Pub 2018. PMID: 29378304.
133. Tamari, R, Oran, B, Hilden, PD, Maloy, M, Kongtim, P, Papadopoulos, EB, Rondon, G, Jakubowski, A, Andersson, BS, Devlin, SM, Ahmed, S, Popat, UR, Ponce, DM, Chen, J, Sauter, C, Young, JW, De Lima, M, Perales, MA, O'Reilly, R, Giralt, S, Champlin, RE, Castro-Malaspina, H. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation 24(5):1079-1087, 2018. e-Pub 2018. PMID: 29325829.
134. Shah, N, Ahn, KW, Litovich, C, Fenske, TS, Ahmed, S, Battiwalla, M, Bejanyan, N, Dahi, PB, Bolaños-Meade, J, Chen, A, Ciurea, SO, Bachanova, V, DeFilipp, Z, Epperla, N, Farhadfar, N, Herrera, AF, Haverkos, B, Holmberg, L, Hossain, N, Kharfan-Dabaja, MA, Kenkre, VP, Lazarus, HM, Murthy, H, Nishihori, T, Rezvani, A, D'Souza, A, Savani, BN, Ulrickson, ML, Waller, EK, Sureda, A, Smith, SM, Hamadani, M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation. Blood Advances 2(8):933-940, 2018. e-Pub 2018. PMID: 29685953.
135. Milgrom, SA, Pinnix, CC, Chi, TL, Vu, T, Gunther, J, Sheu, T, Fowler, N, Westin, JR, Nastoupil, L, Oki, Y, Fayad, LE, Neelapu, SS, Rodriguez, MA, Hagemeister, FB, Fanale, MA, Lee, HJ, Hosing, C, Ahmed, S, Nieto, Y, Shpall, E, Dabaja, BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. International Journal of Radiation Oncology Biology Physics 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
136. Hwang, JP, Lok, AS, Fisch, MJ, Cantor, SB, Barbo, AG, Lin, Y, Foreman, J, Vierling, JM, Torres, HA, Granwehr, BP, Miller, E, Eng, C, Simon, G, Ahmed, S, Ferrajoli, A, Romaguera, JE, Suarez-Almazor, M. Models to predict hepatitis B virus infection among patients with cancer undergoing systemic anticancer therapy. Journal of Clinical Oncology 36(10):959-967, 2018. e-Pub 2018. PMID: 29447061.
137. Oran, B, Saliba, RM, Carmazzi, Y, De Lima, M, Rondon, G, Ahmed, S, Alousi, AM, Andersson, BS, Anderlini, P, Alvarez, M, Bashir, Q, Ciurea, SO, Fernandez-Vina, M, Hosing, C, Kebriaei, P, Korbling, M, Cano, P, Khouri, IF, Marin, D, Nieto, Y, Olson, AL, Popat, UR, Rezvani, K, Qazilbash, MH, Shpall, E, Champlin, RE, Cao, K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
138. Kharfan-Dabaja, MA, Raj, RV, Nikolaenko, L, Ahmed, S, Reddy, N, Nathan, S, Cherry, M, El-Jurdi, N, Obiozor, C, Fenske, TS, Song, JY, Muzzafar, T, Ayala, E, Savani, BN, Khawandanah, M, Caimi, PF, Hamadani, M, Forman, SJ, Hussaini, M, De Lima, M, Olteanu, H, Shah, BD, Chavez, JC, Al Malki, MM, Kumar, A, Ganguly, S. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma. Biology of Blood and Marrow Transplantation 24(3):486-493, 2018. e-Pub 2018. PMID: 29225164.
139. Epperla, N, Ahn, KW, Armand, P, Jaglowski, SM, Ahmed, S, Kenkre, VP, Savani, BN, Jagasia, M, Shah, N, Fenske, TS, Sureda, A, Smith, SM, Hamadani, M. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation 24(1):78-85, 2018. e-Pub 2018. PMID: 29032272.
140. Shah, ND, Cornelison, AM, Saliba, RM, Ahmed, S, Nieto, Y, Bashir, Q, Parmar, S, Hosing, C, Popat, UR, Shpall, E, Champlin, RE, Qazilbash, MH. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. European Journal of Haematology 99(6):532-535, 2017. e-Pub 2017. PMID: 28895206.
141. Kharfan-Dabaja, MA, Al Malki, MM, Deotare, U, Raj, RV, El-Jurdi, N, Majhail, NS, Cherry, M, Bashir, Q, Darrah, J, Nishihori, T, Sibai, H, Hamadani, M, De Lima, M, Gerds, A, Selby, GB, Qazilbash, MH, Forman, SJ, Ayala, E, Lipton, JH, Hari, PN, Muzzafar, T, Zhang, L, Olteanu, H, Perkins, J, Sokol, L, Kumar, A, Ahmed, S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm. British Journal of Haematology 179(5):781-789, 2017. e-Pub 2017. PMID: 28980314.
142. Kharfan-Dabaja, MA, Kumar, A, Ayala, E, Hamadani, M, Reimer, P, Gisselbrecht, C, D'Amore, F, Jantunen, E, Ishida, T, Bazarbachi, A, Foss, FM, Advani, RH, Fenske, TS, Lazarus, HM, Friedberg, JW, Aljurf, M, Sokol, L, Tobinai, K, Tse, E, Burns, LJ, Chavez, JC, Reddy, N, Suzuki, R, Ahmed, S, Nademanee, A, Mohty, M, Gopal, A, Fanale, MA, Pro, B, Moskowitz, AJ, Sureda, A, Perales, MA, Carpenter, P, Savani, BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas. Biology of Blood and Marrow Transplantation 23(11):1826-1838, 2017. e-Pub 2017. PMID: 28797780.
143. Ciurea, SO, Schafer, JR, Bassett Jr, R, Denman, CJ, Cao, K, Willis, D, Rondon, G, Chen, J, Soebbing, D, Kaur, I, Gulbis, A, Ahmed, S, Rezvani, K, Shpall, E, Lee, DA, Champlin, RE. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130(16):1857-1868, 2017. e-Pub 2017. PMID: 28835441.
144. Hwang, JP, Suarez-Almazor, M, Cantor, SB, Barbo, AG, Lin, Y, Ahmed, S, Chavez Mac Gregor, M, Donato-Santana, C, Eng, C, Ferrajoli, A, Fisch, MJ, McLaughlin, P, Simon, G, Rondon, G, Shpall, E, Lok, AS. Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 123(17):3367-3376, 2017. e-Pub 2017. PMID: 28518219.
145. Khouri, M, Jabbour, EJ, Gulbis, A, Turturro, F, Ledesma, C, Korbling, M, Samuels, BI, Ahmed, S, Alousi, AM, Ciurea, SO, Marin, D, Patel, K, Popat, UR, Bueso-Ramos, CE, Bassett Jr, R, Khouri, IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation 23(8):1405-1410, 2017. e-Pub 2017. PMID: 28495642.
146. Yucel, OK, Saliba, RM, Rondon, G, Ahmed, S, Alousi, AM, Bashir, Q, Ciurea, SO, Popat, UR, Khouri, IF, Marin, D, Rezvani, K, Kebriaei, P, Shpall, E, Champlin, RE, Oran, B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
147. Epperla, N, Ahn, KW, Ahmed, S, Jagasia, M, Digilio, A, Devine, S, Jaglowski, SM, Kennedy, V, Rezvani, A, Smith, SM, Sureda, A, Fenske, TS, Kharfan-Dabaja, MA, Armand, P, Hamadani, M. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Journal of Hematology and Oncology 10(1), 2017. e-Pub 2017. PMID: 28606176.
148. Nieto, Y, Valdez, B, Pingali, SR, Bassett Jr, R, Delgado, R, Nguyen, J, Shah, ND, Popat, UR, Jones, R, Andersson, BS, Gulbis, A, Ahmed, S, Bashir, Q, Parmar, S, Patel, K, Myers, AL, Rondon, G, Orlowski, R, Champlin, RE, Qazilbash, MH. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma. The Lancet Haematology 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
149. Shah, ND, Li, L, McCarty, J, Kaur, I, Yvon, E, Shaim, H, Muftuoglu, M, Liu, E, Orlowski, R, Cooper, L, Lee, DA, Parmar, S, Cao, K, Sobieiski, C, Saliba, RM, Hosing, C, Ahmed, S, Nieto, Y, Bashir, Q, Patel, K, Bollard, CM, Qazilbash, MH, Champlin, RE, Rezvani, K, Shpall, E. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
150. Ge, I, Saliba, RM, Maadani, F, Popat, UR, Qazilbash, MH, Pingali, SR, Shah, ND, Ahmed, S, Bashir, Q, Nieto, Y, Champlin, RE, Hosing, C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
151. Abudayyeh, A, Hamdi, A, Abdelrahim, M, Lin, Y, Page, VD, Rondon, G, Andersson, BS, Afrough, A, Martinez, C, Tarrand, JJ, Kontoyiannis, DP, Marin, D, Gaber, AO, Oran, B, Chemaly, RF, Ahmed, S, Abudayyeh, I, Olson, AL, Jones, R, Popat, UR, Champlin, RE, Shpall, E, Rezvani, K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transplant Infectious Disease 19(1), 2017. e-Pub 2017. PMID: 27862740.
152. Kebriaei, P, Bassett Jr, R, Lyons, GR, Valdez, B, Ledesma, C, Rondon, G, Oran, B, Ciurea, SO, Alousi, AM, Popat, UR, Patel, K, Ahmed, S, Olson, AL, Bashir, Q, Shah, ND, Jones, R, Marin, D, Rezvani, K, Nieto, Y, Khouri, IF, Qazilbash, MH, Hosing, C, Shpall, E, Champlin, RE, Andersson, BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
153. Khouri, IF, Sui, D, Jabbour, EJ, Samuels, BI, Turturro, F, Al-Atrash, G, Anderlini, P, Ahmed, S, Oran, B, Ciurea, SO, Marin, D, Olson, AL, Patel, KP, Popat, UR, Ledesma, C, Kadia, TM, Ferrajoli, A, Burger, JA, Jorgensen, JL, Medeiros, LJ, Bassett Jr, R, Gulbis, A. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone marrow transplantation 52(1):28-33, 2017. e-Pub 2017. PMID: 27595282.
154. Oran, B, Jorgensen, JL, Marin, D, Wang, S, Ahmed, S, Alousi, AM, Andersson, BS, Bashir, Q, Bassett Jr, R, Lyons, GR, Chen, J, Rezvani, K, Popat, UR, Kebriaei, P, Patel, KP, Rondon, G, Shpall, E, Champlin, RE. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
155. Gaballa, S, Ge, I, El Fakih, R, Brammer, JE, Kongtim, P, Tomuleasa, C, Wang, S, Lee, DA, Petropoulos, D, Cao, K, Rondon, G, Chen, J, Hammerstrom, AE, Lombardi, L, Al-Atrash, G, Korbling, M, Oran, B, Kebriaei, P, Ahmed, S, Shah, ND, Rezvani, K, Marin, D, Bashir, Q, Alousi, AM, Nieto, Y, Qazilbash, MH, Hosing, C, Popat, UR, Shpall, E, Khouri, IF, Champlin, RE, Ciurea, SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
156. Nieto, Y, Valdez, B, Thall, PF, Jones, R, Wei, W, Myers, AL, Hosing, C, Ahmed, S, Popat, UR, Shpall, E, Qazilbash, MH, Gulbis, A, Anderlini, P, Shah, ND, Bashir, Q, Alousi, AM, Oki, Y, Fanale, MA, Dabaja, BS, Pinnix, CC, Champlin, RE, Andersson, BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-2688, 2016. e-Pub 2016. PMID: 27203405.
157. Hidalgo Lopez, JE, Yabe, M, Carballo-Zarate, AA, Wang, S, Jorgensen, JL, Ahmed, S, Lee, J, Li, S, Schlette, EJ, McDonnell, TJ, Miranda, R, Medeiros, LJ, Bueso-Ramos, CE, Yin, CC. Donor-derived T-cell large granular lymphocytic leukemia in a patient with peripheral T-cell lymphoma. JNCCN Journal of the National Comprehensive Cancer Network 14(8):939-944, 2016. e-Pub 2016. PMID: 27496109.
158. Aung, FM, Lichtiger, B, Rondon, G, Yin, CC, Alousi, AM, Ahmed, S, Andersson, BS, Bashir, Q, Ciurea, SO, Hosing, C, Jones, R, Kebriaei, P, Khouri, IF, Nieto, Y, Oran, B, Parmar, S, Qazilbash, MH, Shah, ND, Shpall, E, Champlin, RE, Popat, UR. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation 22(5):961-965, 2016. e-Pub 2016. PMID: 26921820.
159. Mehta, RS, Saliba, RM, Chen, J, Rondon, G, Hammerstrom, AE, Alousi, AM, Qazilbash, MH, Bashir, Q, Ahmed, S, Popat, UR, Hosing, C, Khouri, IF, Shpall, E, Champlin, RE, Ciurea, SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology 173(3):444-455, 2016. e-Pub 2016. PMID: 26947769.
160. Pinnix, CC, Shah, J, Chuang, HH, Costelloe, C, Medeiros, LJ, Wogan, CF, Reed, VK, Smith, GL, Milgrom, SA, Patel, K, Huo, J, Turturro, F, Romaguera, JE, Fayad, LE, Oki, Y, Fanale, MA, Westin, JR, Nastoupil, L, Hagemeister, FB, Rodriguez, MA, Qazilbash, MH, Shah, ND, Bashir, Q, Ahmed, S, Nieto, Y, Hosing, C, Rohren, E, Dabaja, BS. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 16(3):122-128, 2016. e-Pub 2016. PMID: 26795083.
161. Brammer, JE, Khouri, IF, Gaballa, S, Anderlini, P, Tomuleasa, C, Ahmed, S, Ledesma, C, Hosing, C, Champlin, RE, Ciurea, SO. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation 22(3):493-498, 2016. e-Pub 2016. PMID: 26497906.
162. Yabe, M, Medeiros, LJ, Tang, G, Wang, S, Ahmed, S, Nieto, Y, Hu, S, Bhagat, G, Oki, Y, Patel, KP, Routbort, MJ, Luthra, R, Fanale, MA, Bueso-Ramos, CE, Jorgensen, JL, Vega Vazquez, F, Chen, W, Hoehn, D, Konoplev, SN, Milton, D, Wistuba, II, Li, S, You, MJ, Young, KH, Miranda, R. Prognostic factors of hepatosplenic T-cell lymphoma clinicopathologic study of 28 cases. American Journal of Surgical Pathology 40(5):676-688, 2016. e-Pub 2016. PMID: 26872013.
163. Nieto, Y, Valdez, B, Thall, PF, Ahmed, S, Jones, R, Hosing, C, Popat, UR, Shpall, E, Qazilbash, MH, Gulbis, A, Anderlini, P, Alousi, AM, Shah, ND, Bashir, Q, Liu, Y, Oki, Y, Hagemeister, FB, Fanale, MA, Dabaja, BS, Pinnix, CC, Champlin, RE, Andersson, BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation 21(11):1914-1920, 2015. e-Pub 2015. PMID: 26071868.
164. Oran, B, Cao, K, Saliba, RM, Rezvani, K, De Lima, M, Ahmed, S, Hosing, C, Popat, UR, Carmazzi, Y, Kebriaei, P, Nieto, Y, Rondon, G, Willis, D, Shah, ND, Parmar, S, Olson, AL, Moore, B, Marin, D, Mehta, RS, Fernandez-Vina, M, Champlin, RE, Shpall, E. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-1370, 2015. e-Pub 2015. PMID: 26250579.
165. El Fakih, R, Fox, PS, Popat, UR, Nieto, Y, Shah, ND, Parmar, S, Oran, B, Ciurea, SO, Kebriaei, P, Hosing, C, Ahmed, S, Shah, J, Orlowski, R, Champlin, RE, Qazilbash, MH, Bashir, Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia 15(8):472-476, 2015. e-Pub 2015. PMID: 25963284.
166. Popat, UR, Mehta, RS, Rezvani, K, Fox, PS, Kondo, K, Marin, D, McNiece, I, Oran, B, Hosing, C, Olson, AL, Parmar, S, Shah, ND, Andreeff, M, Kebriaei, P, Kaur, I, Yvon, ES, De Lima, M, Cooper, L, Tewari, P, Champlin, RE, Nieto, Y, Andersson, BS, Alousi, AM, Jones, R, Qazilbash, MH, Bashir, Q, Ciurea, SO, Ahmed, S, Anderlini, P, Bosque, DM, Bollard, CM, Molldrem, JJ, Chen, J, Rondon, G, Thomas, MW, Miller, LP, Wolpe, S, Simmons, PJ, Robinson, SN, Zweidler-McKay, PA, Shpall, E. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-2892, 2015. e-Pub 2015. PMID: 25778529.
167. Pinnix, CC, Smith, GL, Milgrom, SA, Osborne, EM, Reddy, JP, Akhtari, M, Reed, VK, Arzu, I, Allen, P, Wogan, CF, Fanale, MA, Oki, Y, Turturro, F, Romaguera, JE, Fayad, LE, Fowler, N, Westin, JR, Nastoupil, L, Hagemeister, FB, Rodriguez, MA, Ahmed, S, Nieto, Y, Dabaja, BS. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-hodgkin lymphoma. International Journal of Radiation Oncology Biology Physics 92(1):175-182, 2015. e-Pub 2015. PMID: 25863764.
168. Alousi, AM, Brammer, JE, Saliba, RM, Andersson, BS, Popat, UR, Hosing, C, Jones, R, Shpall, E, Khouri, IF, Qazilbash, MH, Nieto, Y, Shah, ND, Ahmed, S, Oran, B, Al-Atrash, G, Ciurea, SO, Kebriaei, P, Chen, J, Rondon, G, Champlin, RE. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biology of Blood and Marrow Transplantation 21(5):906-912, 2015. e-Pub 2015. PMID: 25667989.
169. Pinnix, CC, Dabaja, BS, Ahmed, MA, Chuang, HH, Costelloe, C, Wogan, CF, Reed, VK, Romaguera, JE, Neelapu, SS, Oki, Y, Rodriguez, MA, Fayad, LE, Hagemeister, FB, Nastoupil, L, Turturro, F, Fowler, N, Fanale, MA, Nieto, Y, Khouri, IF, Ahmed, S, Medeiros, LJ, Davis, RE, Westin, JR. Single-institution experience in the treatment of primary mediastinal b cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. International Journal of Radiation Oncology Biology Physics 92(1):113-121, 2015. e-Pub 2015. PMID: 25863759.
170. Pemmaraju, N, Sasaki, K, Johnson, D, Daver, N, Afshar-Kharghan, V, Chen, M, Ahmed, S, Colen, R, Kwon, M, Huh, YO, Borthakur, G. Successful treatment of intracranial hemorrhage with recombinant activated factor VII in a patient with newly diagnosed acute myeloid leukemia. Frontiers in Oncology 5(FEB), 2015. e-Pub 2015. PMID: 25717439.
171. Di Stasi, A, Milton, D, Poon, ML, Hamdi, A, Rondon, G, Chen, J, Pingali, SR, Konopleva, M, Kongtim, P, Alousi, AM, Qazilbash, MH, Ahmed, S, Bashir, Q, Al-Atrash, G, Oran, B, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Lee, DA, De Lima, M, Rezvani, K, Khouri, IF, Champlin, RE, Ciurea, SO. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biology of Blood and Marrow Transplantation 20(12):1975-1981, 2014. e-Pub 2014. PMID: 25263628.
172. Khouri, IF, Wei, W, Korbling, M, Turturro, F, Ahmed, S, Alousi, AM, Anderlini, P, Ciurea, SO, Jabbour, EJ, Oran, B, Popat, UR, Rondon, G, Bassett Jr, R, Gulbis, A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma. Blood 124(14):2306-2312, 2014. e-Pub 2014. PMID: 25145344.
173. Oran, B, Kongtim, P, Popat, UR, De Lima, M, Jabbour, EJ, Lu, X, Chen, J, Rondon, G, Kebriaei, P, Ahmed, S, Andersson, BS, Alousi, AM, Ciurea, SO, Shpall, E, Champlin, RE. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation 20(10):1618-1625, 2014. e-Pub 2014. PMID: 24953017.
174. Sasaki, K, Lu, G, Saliba, RM, Bashir, Q, Hosing, C, Popat, UR, Shah, ND, Parmar, S, Dinh, YT, Ahmed, S, Shpall, E, Kebriaei, P, Shah, J, Orlowski, R, Champlin, RE, Qazilbash, MH. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation 19(8):1227-1232, 2013. e-Pub 2013. PMID: 23733001.

Review Articles

1. Dreger, P, Ahmed, S, Bazarbachi, A, Dietrich, S, Fenske, TS, Ghosh, N, Hermine, O, Hamadani, M. How we treat mantle cell lymphoma with cellular therapy in 2025. Bone marrow transplantation 60(6):759-768, 2025. e-Pub 2025. PMID: 40229536.
2. Perales, MA, Ahmed, S. When to use stem cell transplantation for classical Hodgkin lymphoma. Hematology (United States) 2024(1):517-523, 2024. e-Pub 2024. PMID: 39644064.
3. Al-Juhaishi, T, Ahmed, S. Management of limited-stage Hodgkin lymphoma. Hematology (United States) 2023(1):500-509, 2023. e-Pub 2023. PMID: 38066938.
4. Ullah, F, Dima, D, Omar, N, Ogbue, O, Ahmed, S. Advances in the treatment of Hodgkin lymphoma. Frontiers in Oncology 13, 2023. e-Pub 2023. PMID: 36937412.
5. Markouli, M, Ullah, F, Omar, N, Apostolopoulou, A, Dhillon, P, Diamantopoulos, P, Dower, J, Gurnari, C, Ahmed, S, Dima, D. Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder. Cancers 14(23), 2022. e-Pub 2022. PMID: 36497432.
6. Khan, M, Hagemeister, FB, Wang, L, Ahmed, S. A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Reviews 55, 2022. e-Pub 2022. PMID: 35396126.
7. Steiner, RE, Banchs, J, Koutroumpakis, E, Becnel, M, Gutierrez, C, Strati, P, Pinnix, CC, Feng, L, Rondon, G, Claussen, C, Palaskas, NL, Karimzad, K, Ahmed, S, Neelapu, SS, Shpall, E, Wang, L, Vega Vazquez, F, Westin, JR, Nastoupil, L, Deswal, A. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
8. Al-Juhaishi, T, Ahmed, S. CAR-T in B-Cell Lymphomas. Clinical Lymphoma, Myeloma and Leukemia 22(4):e261-e268, 2022. e-Pub 2022. PMID: 34782260.
9. Al-Juhaishi, T, Borogovac, A, Ibrahimi, S, Wieduwilt, M, Ahmed, S. Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma. Journal of Personalized Medicine 12(2), 2022. e-Pub 2022. PMID: 35207613.
10. Sheikh, MA, Toledano, M, Ahmed, S, Gul, Z, Hashmi, SK. Noninfectious neurologic complications of hematopoietic cell transplantation. Hematology/ Oncology and Stem Cell Therapy 14(2):87-94, 2021. e-Pub 2021. PMID: 32516577.
11. Fang, PQ, Gunther, J, Wu, SY, Dabaja, BS, Nastoupil, L, Ahmed, S, Neelapu, SS, Pinnix, CC. Radiation and CAR T-cell Therapy in Lymphoma. Frontiers in Oncology 11, 2021. e-Pub 2021. PMID: 33842363.
12. Al-Juhaishi, T, Ahmed, S. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Current hematologic malignancy reports 16(1):32-39, 2021. e-Pub 2021. PMID: 33630232.
13. Bachegowda, LS, Saliba, RM, Ramlal, R, Kongtim, P, Chen, J, Rondon, G, Wallis, W, Alousi, AM, Ahmed, S, Hosing, C, Parmar, S, Qazilbash, MH, Khouri, IF, Bashir, Q, Oran, B, Popat, UR, Shpall, E, Marin, D, Rezvani, K, Kebriaei, P, Champlin, RE, Ciurea, SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
14. Ahmed, S, Winter, JN, Gordon, LI, Evens, AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma. Leukemia and Lymphoma 51(7):1163-1177, 2010. e-Pub 2010. PMID: 20470217.

Other Articles

1. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
2. Zhang, S, Jiang, VC, Han, G, Hao, D, Lian, J, Liu, Y, Cai, Q, Zhang, RJ, McIntosh, J, Wang, R, Dang, M, Dai, E, Wang, Y, Santos, DA, Badillo, M, Leeming, A, Chen, Z, Hartig, K, Bigcal, J, Zhou, J, Kanagal-Shamanna, R, Ok, CY, Lee, H, Steiner, RE, Zhang, J, Song, X, Nair, R, Ahmed, S, Rodriquez, A, Thirumurthi, S, Jain, P, Wagner-Bartak, N, Hill, H, Nomie, K, Flowers, CR, Futreal, A, Wang, L, Wang, L Author Correction. Nature communications 15(1), 2024. PMID: 39375332.

Abstracts

1. Nieto Y, MD, Banerjee PP, PhD, Kaur I, PhD, Griffin L, Ganesh C, Kerbauy L, MD, Basar R, MD, Kaplan M, MS, Islam S, Esqueda D, Bassett R, MS, Timmons M, PA-C, Ramdial JL, MD, Srour SA, MD, MS, Saini N, MD, Hosing C, MD, Ahmed S, MD, Iyer SP, MD, Alexis K, MD, Emig M, MD, Harstrick A, MD, Shpall EJ, MD, Rezvani K, MD. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood Journal, 2022. e-Pub 2022.
2. Nieto Y, MD, Valdez BC, PhD, Thall PF, PhD, Ramdial JL, MD, Srour SA, MD, MS, Hosing C, MD, Saini N, MD, Alousi AM, MD, Qazilbash MH, MD, Popat UR, MD, Gulbis A, PharmD, Shigle TL, PharmD, Bassett R, MS, Guillermo-Pacheco M, Ledesma C, Strati P, MD, Ahmed S, MD, Steiner R, MD, Westin J, MD, Nair R, MD, Iyer SP, MD, Champlin RE, MD, Shpall EJ, MD, Andersson BS, MD, PhD. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood 140(1), 2022. e-Pub 2022.
3. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin J, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections. Blood 140(1), 2022. e-Pub 2022.
4. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Iyer SP, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. Blood 140(1), 2022. e-Pub 2022.
5. Nze C, Andersen CR, Ayers A, Westin J, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, McNeil L, Nguyen L, Nastoupil LJ, Flowers CR. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution. Blood 140(1), 2022. e-Pub 2022.
6. Yeh J, Saliba RM, Wang C, Fang Z, Figgins B, Ahmed S, Yilmaz M, Daver N, Mehta RS, Alatrash G, Marin D, Popat UR, Champlin RE, Shpall EJ, Oran B. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. Blood 140(1), 2022. e-Pub 2022.
7. Khurana A, Bailey M, Iqbal M, Bansal R, Lee CJ, Hunter B, Lunning MA, Jaglowski S, Jain MD, Dahiya S, Bachanova V, Farooq U, Ahmed S, Hill BT, Munoz JL, Patel K, Oluwole OO, Lin Y. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes. Blood 140(1), 2022. e-Pub 2022.
8. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. Blood 140(1), 2022. e-Pub 2022.
9. Khawaja F, Prakash R, Sassine J, Handley G, VanWieren T, Angelidakis G, Iyer SP, Ramdial JL, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly R. Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center. Blood 140(1), 2022. e-Pub 2022.
10. Ahmed S, Flinn IW, Mei M, Riedell PA, Armand P, Grover NS, Balyan R, Ding C, Myo A, Horak ID, Heslop HE. Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial). Blood 140(1), 2022. e-Pub 2022.
11. Ebinama U, Sheshadiri A, Ahmed S, Lee HJ, Liu M, Iyer SP. Risk of Pneumonitis with Immune Checkpoint Inhibitors in Hodgkin's Lymphoma and Other Hematologic Malignancies: A Retrospective Review from Pharmacovigilance. Blood 140(1), 2022. e-Pub 2022.
12. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin J, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. Blood 140(1), 2022. e-Pub 2022.
13. Lunning MA, Wang H, Hu Z, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Miao H, Shahani S, Patel AR, Spooner C, Fu C, Xu H, Pasquini MC. Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies. Blood 140(1), 2022. e-Pub 2022.
14. Patel K, Riedell PA, Tilly H, Ahmed S, Michot J, Ghesquieres H, de Collela JMS, Chanan-Khan A, Bouabdallah K, Tessoun B, Iyengar S, Long M, Clynes R, Klianodia J, Bao L, Ding Y, Jin J, Ainsworth WB, Garcha R, Kye S, Phillips TJ. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis. Blood 140(1), 2022. e-Pub 2022.
15. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros L, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood 140(1), 2022. e-Pub 2022.
16. Perales M, Ahmed S, Dahiya S, Riedell PA, McGuirk JP, Oluwole OO, Chaudhry SA, Lee Z, Dai S, Dixit N, Fanton C, Marcondes MQ, Zalevsky J, Tagliaferri MA, Turtle CJ. A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood 140(1), 2022. e-Pub 2022.
17. Mirza A, Hosing C, Foss FM, Kim S, Moskop A, Oloyede T, Ahmed S, Hematti P, Turtle CJ, Pasquini MC, Gowda L. Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR). Blood 140(1), 2022. e-Pub 2022.
18. Lunning MA, DO, FACP, Wang H, MPH, Hu Z, MPH, Locke FL, MD, Siddiqi T, MD, Jacobson CA, MD, Ahmed S, MD, Miklos DB, MD, PhD, Lin Y, MD, PhD, Hill BT, MD, PhD, Ghobadi A, MD, Neelapu SS, MD, Westin J, MD, Miao H, MD, PhD, Shahani S, MD, Patel AR, PhD, Spooner C, MBBS, BSc, Fu C, PhD, Xu H, MD, PhD, Pasquini MC, MD, MS. Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy. Blood 140(1):1852–1855, 2022. e-Pub 2022.
19. Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramdial JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. Blood 140(1), 2022. e-Pub 2022.
20. Khouri IF, Hwang H, Neelapu SS, Wang X, Hosing C, Ahmed S, Kebriaei P, Daher M, Olson AL, Anderlini P, Im JS, Westin J, Shpall EJ, Champlin RE, Nastoupil LJ. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. Blood 140(1), 2022. e-Pub 2022.
21. Jain P, Ok CY, Fetooh A, Kanagal-Shamanna R, Jelloul FZ, Hill H, Floyd K, Loghavi S, Zuo Z, Yin C, Routbort M, Tang G, Ahmed S, Malpica Castillo LE, Siddiqui A, Chen W, Oriabure O, Badillo M, Steiner RE, Iyer SP, Lee HJ, Luthra R, Vega F, Flowers CR, Medeiros J, Wang ML, Patel KP, Fowler NH, Nair R. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma 140(1), 2022. e-Pub 2022.
22. Kurtz DM, Ahmed S, Tong CK, Mei M, Ding C, Flinn IW, Riedell PA, Hogan GJ, Schultz A, Chabon JJ, Heslop HE, Myo A, Alizadeh AA, Horak ID. Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial). Blood 140(1), 2022. e-Pub 2022.
23. Locke FL, Hu Z, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Miao H, Shahani S, Spooner C, Fu C, Patel AR, Xu H, Pasquini MC. Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel. Blood 140(1), 2022. e-Pub 2022.
24. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Ahmed S, Steiner RE, Nair R, Strati P, Westin J, Fayad L, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara D, Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma. Blood 140(1), 2022. e-Pub 2022.
25. Strati P, Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood 140(1), 2022. e-Pub 2022.
26. Elias A, Prakash R, Nastoupil LJ, Fowler NH, Ahmed S, Nair R, Malpica Castillo LE, Dabaja BS, Xu J, Medeiros J, Stewart J, Wang W, Pinnix CC, Hunt K, Clemens MW, Miranda RN, Iyer SP. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin. Blood 140(1), 2022. e-Pub 2022.
27. Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Awan FT, Farooq U, Ganguly S, Hematti P, Jain MD, Kebriaei P, Locke FL, Mead E, Nishihori T, Olson AL, Pennisi M, Perales M, Geethakumari PR, Shouval R, Shpall EJ, Magalhaes-Silverman MM, Strouse C, Turtle CJ, Vallurupalli A, Wudhikam K, Pasquini MC, Ahmed S, Sorror M. Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART). Blood 140(1), 2022. e-Pub 2022.
28. S A, furqan F, Strati P, Westin J, Fayad L, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner R, Wang M, Pinnix CC, Flowers C, Horowitz SB, Hawkins M, Neelapu SS. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). . J Clin Oncol 38(Suppl), 2020. e-Pub 2020.
29. Strati P, Tummala S, Nastoupil LJ, Westin JR, Fayad L, S A, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang ML, Pinnix CC, Adkins S, Claussen CM, Martinez C, Hawkins M, Johnson N, George S, Neelapu SS, Chi L. Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma . Blood 134(Suppl 1):765, 2019. e-Pub 2019.
30. estin JR, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, S A, Rodriguez MA, Lee HJ, Steiner RE, Nair R, Parmar S, Young KH, McDonnell TJ, Chuang H, Green MR, Neelapu SS, Davis E. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results . Blood 134(Suppl 1):1581, 2019. e-Pub 2019.
31. Westin JR, Fowler NH, Nastoupil LJ, Neelapu SS, Lee H, Hagemeister FB, Rodriguez MA, Steiner RE, S A, Parmar S, Nair R, Harrison R, Fayad L. A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma . Blood 134(Suppl 1), 2019. e-Pub 2019.
32. Ghosh N, S A, Litovich C, Ahn KW, Khanal M, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M. Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis . Blood 134(Suppl 1):319, 2019. e-Pub 2019.
33. Hamid MS, Rutherford SC, Kim S, Bartlett NL, M-K M, Watkins M, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, S A, Stephens DM, Allen P, Patel K, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Pagel JM, Ramchandren R. North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma . Blood 134(Suppl 1):153, 2019. e-Pub 2019.
34. Jain P, Kanagal-Shamanna R, Ok CY, G-P O, Navsaria L, Nogueras González GM, Zhang S, Han G, Ghorab A, Boddu P, Hagemeister FB, Lee HJ, Nomie K, Jiang C, Fayad L, Westin JR, Nastoupil LJ, S A, Iyer SP, Champlin RE, Neelapu SS, Romaguera JE, Fowler NH, Tang G, Li S, Patel K, Thirumurthi S, Tinsu P, Xu G, Wang L, Wang ML. Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients . Blood 134(Suppl 1):1526, 2019. e-Pub 2019.
35. S A, Lisano J, Newhook T. A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL . Blood 134(Suppl 1), 2019. e-Pub 2019.
36. Olson AL, Lin R, Bdaiwi M, Thall PF, Rafei H, Kaur I, Li L, Abueg G, Timmons M, Chemaly R, Marin D, Alousi AM, S A, Ciurea SO, Hosing C, Kebriaei P, Jones RB, Andersson BS, Oran B, Abuddayeh A, Popat U, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation . Blood 134(Suppl 1), 2019. e-Pub 2019.
37. S A, Ghosh N, Khanal M, Ahn KW, Litovich C, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis . Blood 134(Suppl 1), 2019. e-Pub 2019.
38. Nastoupil LJ, Westin JR, Hagemeister FB, Lee HJ, Fayad L, Samaniego F, S A, Claret L, Steiner RE, Nair R, Parmar S, Rodriguez MA, Wang ML, Green MR, Davis E, Neelapu SS, Fowler NH. Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL) . Blood 134(Suppl 1), 2019. e-Pub 2019.
39. Pinnix CC, Gunther JR, Dabaja BS, Adkins S, Hawkins M, Westin JR, Fayad L, S A, Fowler NH, Hagemeister FB, Iyer SP, Rodriguez MA, Lee HJ, Steiner RE, Nair R, Strati P, Parmar S, Samaniego F, Wang M, Neelapu SS, Nastoupil LJ. Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma . Blood 134(Suppl 1):1609, 2019. e-Pub 2019.
40. Burns E, Anand K, Westin JR, Pingali SRK, Ensor J, Sano D, Nastoupil LJ, Lee HJ, Nieto Y, Khouri IF, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad LE, Steiner RE, Nair R, S A, Fowler NH, Neelapu SS, Iyer SP. Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Clinical Studies, and MD Anderson . Blood 134(Suppl 1):1931, 2019. e-Pub 2019.
41. Iyer SP, Neelapu SS, Burns E, Nair N, Hosing C, Nieto Y, Westin JR, Parmar S, Fowler NH, Nastoupil LJ, Duvic M, Miranda RN, Lee HJ, Samaniego F, S A, Lei F, Huen A. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) . Blood 134(Suppl 1):1546, 2019. e-Pub 2019.
42. Jain P, Lee HJ, Steiner RE, Hagemeister FB, Samaniego F, Westin JR, Nastoupil LJ, S A, Iyer SP, Romaguera JE, Zhao S, Nomie K, Ok CY, Kanagal-Shamanna R, Oriabure O, Xu G, Zhang L, Jiang C, Jung D, Navsaria L, Chen W, Moghrabi O, Nizam T, McClain CM, Badillo M, Thirumurthi S, Santos D, Tang G, Patel K, Neelapu SS, Wang L, Fowler NH, Wang ML. Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial . Blood 134(Suppll 1):3988, 2019. e-Pub 2019.
43. Anand K, Burns E, Sano D, Pingali SR, Westin J, Nastoupil LJ, Lee HJ, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad L, Steiner R, Nair R, S A, Fowler NH, Neelapu SS, Iyer SP. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. . J Clin Oncol (ASCO) 37(Suppl 1), 2019. e-Pub 2019.
44. Westin J, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, S A, Rodriguez MAR, Lee HL, Steiner R, Nair R, Parmar S, Young KH, McDonnell T, Chuang H, Green MR, Neelapu SS, Davis RE. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. . J Clin Oncol (ASCO) 37(Suppl 1), 2019. e-Pub 2019.
45. Strati P, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad L, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich V, Ariza-Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. . J Clin Oncol (ASCO) 37(Suppl 1), 2019. e-Pub 2019.
46. Casulo C, Friedberg J, Ahn K, Flowers C, DiGilio A, Smith S, Ahmed S, Inwards D, Aljurf M, Chen A, Choe H, Cohen J, Copelan E, Farooq U, Fenske T, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble R, Kenkre V, Lazarus H, Lazaryan A, Olsson R, Rezvani A, Rizzieri D, Seo S, Shah G, Shah N, Melham S, Sureda A, William B, Cumpston A, Zelenetz A, Link B, Hamadani M. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2018. e-Pub 2018.
47. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Miller E, Kaseb A, Sturgis E, Angelidakis G, Ahmed S, Ferrajoki A, Samaniego F, Hawk E, Hwang JP. Hepatitis C Virus Risk Tool for Patients with Cancer. American Society of Clinicial Oncology (ASCO). e-Pub 2018.
48. Shah N, Mehta R, Li L, Mccarty J, Kaur I, Orlowski RZ, Cooper L, Lee DA, Cao K, Parmar S, Hosing C, S A, Nieto Y, Bashir Q, Patel KK, Bollard C, Qazilbash MH, Champlin RE, Rezvani K, Shpall EJ. Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma. 36(Suppl), 2018. e-Pub 2018.
49. Tabchi S, Nair R, Patel KK, Lee HC, Thomas SK, Amini B, S A, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). . J Clin Oncol (ASCO) 36(Suppl), 2018. e-Pub 2018.
50. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood 130(Suppl 1):399, 2017. e-Pub 2017.
51. Khouri IF, Gulbis AM, Milton DR, Korbling M, Ledesma C, Ahmed S, Alousi AM, Oran B, Anderlini P, Ciurea SO, Bassett Jr RL, Jabbour EJ. Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies. Blood 130(Suppl 1):3240, 2017. e-Pub 2017.
52. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood 130(Suppl 1):4365, 2017. e-Pub 2017.
53. Oran B, Saliba RM, Jorgensen JL, Shah MV, Marin DC, Wang SA, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Popat U, Rondon G, Kebriaei P, Shpall EJ, Champlin RE. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. Blood 130(Suppl 1):2031, 2017. e-Pub 2017.
54. Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130(Suppl 1):2007, 2017. e-Pub 2017.
55. Ciurea SO, Soebbing D, Rondon G, Cao K, Alatrash G, Ahmed S, Popat U, Oran B, Bashir Q, Kebriaei P, Kaur I, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation. Blood 130(Suppl 1):3179, 2017. e-Pub 2017.
56. Gowda L, Alijadayeh M, Marin DC, Ledesma C, Rondon G, Popat U, Alousi AM, Oran B, Shah MV, Ahmed S, Kanagal-Shamanna R, Ciurea SO, Shpall EJ, Luthra R, Hosing C, Qazilbash MH, Rezvani K, Jabbour EJ, Patel KP, Ravandi F, Kantarjian HM, Champlin RE, Kebriaei P. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Blood 130(Suppl 1):1992, 2017. e-Pub 2017.
57. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 130(Suppl 1):3267, 2017. e-Pub 2017.
58. Nieto Y, Thall PF, Valdez B, Ma J, Timmons M, Trapp M, Ahmed S, Shpall EJ, Jones RB, Hosing C, Anderlini P, Popat U, Qazilbash MH, Alousi A, Gulbis AM, Ledesma C, Champlin RE, Andersson BS. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas. Blood 130(Suppl 1):1966, 2017. e-Pub 2017.
59. Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Anderson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, Champlin RE. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. Blood 130(Suppl 1):1938, 2017. e-Pub 2017.
60. Popat UR, Saliba R, Oran B, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Valdez B, Jones RB, Shpall EJ, Andersson B, Champlin RE. Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS. . J Clin Oncol (ASCO) 35(Suppl), 2017. e-Pub 2017.
61. Hwang J, Suarez-Almazor ME, Cantor SB, Barbo AG, Lin HY, S A, Chavez-Mac Gregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch M, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok ASF. Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy. . J Clin Oncol (ASCO) 35(Suppl), 2017. e-Pub 2017.
62. Ciurea S, Lee D, Denman C, Schafer J, Bassett R, Cao K, Rondon G, Chen J, Soebbing D, Willis D, Ahmed S, Bashir Q, Kebriaei P, Khouri I, Oran B, Parmar S, Popat U, Hosing C, Yvon E, Rezvani K, Shpall E, Champlin R. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Blood 128(22), 2016. e-Pub 2016.
63. Yucel O Saliba R, Rondon G, Ahmed S, Alousi A, Andersson B, Bashir Q, Ciurea S, Khouri I, Nieto Y, Popat U, Marin M, Rezvani K, Kebriaei P, Shah N, Olson A, Shpall E, Champlin R, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 128(22), 2016. e-Pub 2016.
64. Muftuoglu M, Ahmed S, Olson A, Mulanovich V, Li L, Verstovsek S, Kaur I, Abueg G, Marin D, Yvon E, Champlin R, Shpall E, Rezvani K. Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy. Blood 128(22), 2016. e-Pub 2016.
65. Olson A, Muftuoglu M, Kaur I, Abueg G, Chemaly R, Yvon E, Thall P, Marin D, Alousi A, Ahmed S, Ciurea S, Hosing C, Kebriaei P, Jones R, Andersson B, Shah N, Oran B, Abudayyeh A, Popat U, Champlin R, Shpall E, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansioin for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. Blood 128(22), 2016. e-Pub 2016.
66. Oran B, Muftuoglu M, Kaur I, Yvon E, Abueg G, Bassett R, Thall P, Marin D, Alousi A, Ahmed S, Ciurea S, Shah N, Hosing C, Olson A, Parmar S, Jones R, Popat U, Andersson B, Champlin R, Shpall E, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. Blood 128(22), 2016. e-Pub 2016.
67. Cerrada S, Marin D, Rondon G, Ledesma C, Popat U, Olson A, Alousi A, Oran B, Ahmed S, Ciurea S, Patel K, Shpall E, Hosing C, Qazilbash M, Shah N, Rezvani K, Jabbour E, Kantarjian H, Champlin R, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood 128(22), 2016. e-Pub 2016.
68. Kebriaei P, Wei W, Thall P, Ledesma C, Valdez B, Popat U, Olson A, Alous A, Oran B, Ahmed S, Ciurea S, Patel K, Shpall E, Hosing C, Qazilbash M, Shah N, Marin D, Rezvani K, Nieto Y, Champlin R, Andersson B. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood 128(22), 2016. e-Pub 2016.
69. Kongtim P, Adekola K, Milton D, Ramlal R, JImenez A, Chen J, Rondon G, Ahmed S, Oran B, Popat U, Cortes J, Champlin R, Ciurea S. Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. Blood 128(22), 2016. e-Pub 2016.
70. Cerrada S, Marin D, Rondon G, Ledesma C, Popat U, Olson A, Alousi A, Oran B, Ahmed S, Ciurea S, Patel K, Shpall E, Hosing C, Qazilbash M, Shah N, Rezvani K, Jabbour E, Kantarjian H, Champlin R, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood 128(22), 2016. e-Pub 2016.
71. Nieto Y, Bassett R, Hosing C, Jones R, Valdez B, Kingham A, Ahmed S, Alousi A, Anderlini P, Popat U, Qazilbash M, Shpall E, Kebriaei P, Brammer J, Oki Y, Fanale M, Maadani F, Rondon G, Champlin R, Andersson B. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplant (ASCT). Biology of Blood and Marrow Transplantation 22(3 Supplement 1):S227, 2016. e-Pub 2016.
72. Lyons G, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Anderlini P, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriari P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Patel K, Qazilbash M, Rezvani K, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. Biology of Blood and Marrow Transplantation 22(3 Supplement 1):S33, 2016. e-Pub 2016.
73. Kebriaei P, Basset R, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin R, Andersson B. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood 126(23), 2015. e-Pub 2015.
74. Nieto Y, Valdez B, Thall P, Wei W, Jones R, Hosing C, Ahmed S, Popat U, Shpall E, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Hagemeister F, Champlin R, Andersson B. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood 126(23), 2015. e-Pub 2015.
75. Gaballa S, Ge I, El Fakih R, Brammer J, Wang S, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Al-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall E, Khouri I, Champlin R, Ciurea S. Results of a Tw9-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem Cell Transplantation. Blood 126(23), 2015. e-Pub 2015.
76. Oran B, Jorgensen J, Wang S, Marin D, Popat U, Chen J, Ciurea S, Ahmed S, Bashir Q, Rezvani K, Shpall E, Kebriaei P, Champlin R. Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype are the Major Prognostic Factors for Relapse after HCT. Blood 126(23), 2015. e-Pub 2015.
77. Popat U, Ray G, Bassett R, Poon M, Valdez B, Konoplev S, Ahmed S, Alousi A, Andersson B, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash M, Rezvani K, Shah N, Shpall E, Champlin R. Eltromopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Duble Blind Placebo Controlled Trial. Blood 126(23), 2015. e-Pub 2015.
78. Mehta R, Saliba R, Chen J, Rondon G, Hammerstrom A, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall E, Champlin R, Ciurea S. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. Blood 126(23), 2015. e-Pub 2015.
79. Khouri I, Sui D, Turturro F, Erwin W, Bassett R, Korbling M, Valverde R, Ahmed S, Alousi A, Anderlini P, Bashir Q, Ciurea S, Oran B, Olson A, Popat U, Patel K, Qazilbash M, Fanale M, Fayad L, Nastoupil L, Westin J, Gulbis A, Medeiros J, Young K, Jessop A. In-Vivo Purging with Rituximab (R) Followed by Z/BEAM vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood 126(23), 2015. e-Pub 2015.
80. Khouri I, Saliba R, Ledesma C, Jabbour E, Turturro F, Al-atrash G, Ahmed S, Oran B, Patel K, Olson A, Marin D, Popat U, Suki T, Jorgensen J, Medeiros J, Gulbis A. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapses/Refractor Chronic Lymphocytic Leukemia (CLL). Blood 126(23), 2015. e-Pub 2015.
81. Im J, Saliba R, Abraham S, Rashid A, Ross W, Nieto Y, Shpall E, Oran B, Olson A, Ahmed S, Popat U, Rondon G, Champlin R, Qazilbash M, Shah N, Alousi A. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft vs. Host Disease. Blood 126(23), 2015. e-Pub 2015.
82. Ramlal R, Gaballa S, Chen J, Rondon G, Oran B, Ahmed S, Bashir Q, Rezvani K, Marin D, Alousi A, Kebraei P, Qazilbash M, Hosing C, Popat U, Shpall E, Champlin R, Ciurea S. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. Blood 126(23), 2015. e-Pub 2015.
83. Alousi A, Bassett R, Chen J, Overman B, Hosing C, Popat U, Shpall E, Nieto Y, Qazilbash M, Khouri I, Kebriaei P, Ahmed S, Shah N, Rezvani K, Kondo K, Ciurea S, Hymes S, Neumann J, Molldrem J, Plair T, Champlin R. A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood 126(23), 2015. e-Pub 2015.
84. Nieto Y, Bassett R, Anderlini P, Hosing C, Alousi A, Popat U, Andersson B, Valdez B, Shpall E, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale M, Hagemeister F, Dabaja B, Pinnix C, Milgrom S, Tewari P, Champlin R, Jones R. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melhalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in odgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched cohort Treated with BEAM. Blood 126(23), 2015. e-Pub 2015.
85. Desai P, Chen J, Liu D, Wu J, Ahmed S, Oran B, Ciurea S, Alousi A, Verstovsek S, Champlin R, Popat U. Patient Choice and Lack of Medicare Coverage for HCT are the Major Reasons Why Transplant Eligible Myelofibrosis Patients Do Not Undergo Transplant. Blood 126(23), 2015. e-Pub 2015.
86. Chihara D, Oki Y, Westin J, Nastoupil L, Fayad L, Samaniego F, Wesson E, Ruben C, Horowitz S, Feng L, Garg N, Ahmed S, Khouri I, Hosing C, Romaguera J, Fowler N, Fanale M. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etopoiside) in Patients with Relpased or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood 126(23), 2015. e-Pub 2015.
87. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski R, Cooper L, Lee D, Parmar S, Cao K, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, McNiece I, Qazilbash M, Champlin R, Rezvani K, Shpall E. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. Blood 126(23), 2015. e-Pub 2015.
88. Popat U, Fox P, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash M, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan is Safe in Older Patients. Blood, 2014. e-Pub 2014.
89. Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat U, Alousi A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood, 2014. e-Pub 2014.
90. Mian I, Milton D, Popat U, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah J, Orlowski R, Qazilbash M, Bashir Q, Champlin R. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologus Stem Cell Transplantations. Blood, 2014. e-Pub 2014.
91. Tamari R, Oran B, Hilden P, Papadopoulos E, Kongtim P, Rondon G, Jakubowski A, Andersson B, Devlin S, Ahmed S, Young J, Popat U, Chen J, de Lima M, O'Reilly R, Giralt S, Champlin R, Castro-Malaspina H. Allo-HSCT for Advanced Myelodysplastic Syndrome: MSKCC vs MDACC. Blood, 2014. e-Pub 2014.
92. Oran B, Rima S, Andersson B, de Lima M, Popat U, Khouri I, Kebriaei P, Bashir Q, Ahmed S, Shpall E, Champlin R, Rondon G. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood, 2014. e-Pub 2014.
93. Khouri I, Saliba R, Xu-Monette Z, Korbling M, Rondon G, Valverde R, Alousi A, Anderlini P, Ahmed S, Ciurea S, Fayad L, Oran B, Parmar S, Popat U, Westin J, Turturro F, Medeiros J, Gulbis A, Young K. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood, 2014. e-Pub 2014.
94. Chihara D, Oki Y, Fayad L, Wesson E, Ruben C, Horowitz S, Wollery J, Feng L, Garg N, Ahmed S, Khouri I, Fanale M. Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2014. e-Pub 2014.
95. Gaballa S, Kongtim P, Rondon G, Chen J, Popat U, Ahmed S, Hosing C, Oran B, Kebriaei P, Parmar S, Shah N, Khouri I, Champlin R, Ciurea S. Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malgnancies: The MD Anderson Cancer Experience. Blood, 2014. e-Pub 2014.
96. Adekola K, di Stasi A, Ferro R, Ahmed S, de Lima M, Oran B, Andersson B, Quntas-Cardama A, Jabbour E, Kantarjian H, Cortes J, Champlin R, Ciurea S. Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation 20(2 Supplement 1):S213, 2014. e-Pub 2014.
97. Ahmed S, Di Stasi A, Shpall E, Khouri I, Alousi A, Ciurea S, Bashir Q, Qazilbash M, Jones R, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing C, Oran B, Andreeff M, Anderlini P, Andersson B, Champlin R, Popat U. Development of Donor Cell Derived Leukemia after Allogeneic Stem Cell Transpant. Blood 122(21), 2013. e-Pub 2013.
98. Di Stasi A, Poon L, Ferro R, Milton D, Rondon G, Wang S, Hamdi A, Qazilbash M, Ahmed S, Khouri I, Oran B, Hosing C, Kebriaei P, Alousi A, Popat U, Shpall E, Lee D, Rezvani K, Champlin R, Ciurea S. Transplant Outcomes for Patients with AML/MDS Using Melphalan-Based Conditioning. Blood(122):21, 2013. e-Pub 2013.
99. Khouri I, Saliba R, Challagundia P, Ledesma C, Korbling M, Gulbis A, Guillermo-Pacheco M, Ahmed S, Anderlini P, Bashir Q, Oran B, Ciurea S, Hosing C, Kebriaei P, Popat U, Jabbour E, Champlin R, Jorgensen J. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 122(21), 2013. e-Pub 2013.
100. Khouri I, Wei W, Valverde R, Korbling M, Turturro F, Gulbis A, Guillermo-Pacheco M, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea S, Hosing C, Popat U, Jabbour E, Champlin R, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression without Myelosuppression. Blood 122(21), 2013. e-Pub 2013.
101. Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson B, Bashir Q, Ciurea S, Hosing C, Parmar S, Qazilbash M, Popat U, Nieto Y, Alousi A, Jones R, Rezvani K, de Lima M, Shpall E, Champlin R, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) in Adult Acute Lymphoblatic Leukemia (ALL) with First Complete Remission (CR). Blood 122(21), 2013. e-Pub 2013.
102. Popat U, Oran B, Hosing C, Kebriaei, Rezvani K, Parmar S, Shah N, Bollard C, Molldrem J, Nieto Y, Andersson B, Alousi A, Jones R, Cooper L, Qazilbash M, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty, Rondon G, Nunsell M, McNiece I, Kaur I, Yvon E, Annadale K, Olchesky S, de Lima M, Champlin R, Miller L, Paradiso L, Koh L, Zweidler-McKay P, Shpall E. Ex Vivo Fucosylation of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 122(21), 2013. e-Pub 2013.
103. Pingali S, Denai M, Di Stasi A, Kebriaei P, Popat U, Alousi A, Anderlini P, Parmar S, Hosing C, Andersson B, Bashir Q, Ahmed S, Oran B, Shpall E, Khouri I, Konopleva M, Alatrash G, Champlin R, Ciurea S. Haploidentical Transplantation for Patients with Advanced Hematologic Malignancies with Melphalan-Based Conditioning Interim Results from a Phase II Clinical Trial. Blood 122(21), 2013. e-Pub 2013.
104. Nieto Y, Thall P, Valdez B, Hosing C, Ahmed S, Jones R, Shah N, Anderlini P, Qazilbash M, Popat U, Bashir Q, Shpall E, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale M, Fowler N, Hagemeister F, Romaguera J, Champlin R, Andersson B. Vorinostat (SAHA) Combined with High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients with Refractory Lymphomas. Blood 122(21), 2013. e-Pub 2013.
105. Shah J, Baladandayuthapani V, Weber D, Thomas S, Alexanian R, Wang M, Qazilbash M, Champlin R, Shah N, Bashir Q, Popat U, Nieto Y, Ahmed S, Parmar S, Orlowski R. Phase II Study of the Combinatin of MLN 9708 with Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 122(21), 2013. e-Pub 2013.
106. Jimenez A, de Lima M, Popat U, Borthakur G, Abruzzo L, Andersson B, Garcia-Manero G, Jabbour E, Chen J, Bashir Q, Ciurea S, Kebriaei P, Ahmed S, Khouri I, Kongtim P, Qazilbash M, Rondon G, Shpall E, Champlin R, Oran B. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). Journal of Clinical Oncology 31(15), 2013. e-Pub 2013.
107. Cornelison A, Dinh Y, Ahmed S, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shah J, Shpall E, Champlin R, Qazilbash M. Younger (<50 years) multiple myeloma (MM) patients (pts) treated with novel agents and autologous haematoopoietic stem cell transplantation (auto-HCT) have longer overall survival than older pts (>50 years). Bone Marrow Transplantation 48(Supplement 2):S205, 2013. e-Pub 2013.
108. Ahmed S, Saliba R, de Lima M, Fisher T, Rondon G, Kebriaei P, Alousi A, Hosing C, Bashir Q, Andersson B, Champlin R. International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation. Blood 120(21):1997, 2012. e-Pub 2012.
109. Ahmed S, Saliba R, de Lima M, Rondon G, Kebriaei P, Fiser T, Jabbour E, Chen J, Kantarjian H, Anderlini P, Alousi A, Hosing C, Andersson B, Jones R, Qazilbash M, Shpall E, Giralt S, Champlin R. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. Blood 120(21), 2012. e-Pub 2012.
110. Ciurea S, Lee D, Cao K, Rondon G, Chen J, Willis D, Ahmed S, Yvon E, Rezvani K, Shpall E, Champlin R. Phase I Trial of IL-21 Ex Vivo Expaned NK Cells Administration to Prevent Disease Relapse after Haploidenticl Stem-Cell Transplantation for Myeloid Leukemias. Blood 126(23), 2012. e-Pub 2012.
111. Ahmed S, Dinh Y, Rondon G, Andersson B, Jones R, Bashir Q, Shah N, Popat U, Champlin R, Qazilbash M, Kebriaei P. Comparison of Busulfan _ Melphalan to Melphalan to Melphalan 200 MG/M2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 18(2 Supplement 2):S251, 2012. e-Pub 2012.
112. Ahmed S, Chiattone A, Jones R, Shpall E, Farhan S, Rondon G, Nieto Y, Bashir Q, Chen J, Khouri I, Kebriaei P, Anderlini P, Champlin R, de Lima M. Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor ERS. Blood 118(21):893, 2011. e-Pub 2011.
113. Ahmed S, Dinh Y, Qureshi S, Rondon G, Bashir Q, Parmar S, Avery T, Orlowski R, Champlin R, Qazilbash M, Shah N. Survival Disparities between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma are Eliminated in the ERA of Novel Therapeutics. Blood 118(21):881, 2011. e-Pub 2011.
114. Ahmed S, Lin H, Baladandayuthapani V, Khan M, Lu G, Rondon G, Qureshi S, Dinh Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Giralt S, Orlowski R, Shah J, Champlin R. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 118(21):893, 2011. e-Pub 2011.
115. Ahmed S, Evens A, Bhalla S, Amareshwar S, James C, Yang S, Prachand S, Dokic D, Gascoyne R, Winter J, Schumacker P, Gordon L. Hypoxia Inducible Factor 1a (HIF-1a) Regulates CD20 Expression in Lymphoma Cells: Possible Implications for Rituximab Based Therapy in Diffuse Large B Cell Lymphoma (DLBCL). Blood 114(22):1698, 2009. e-Pub 2009.
116. Bhalla S, Gordon L, Amareshwar S, Ahmed S, Dokic D, James C, Schumacker P, Evens A. PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells. Blood 114(22):2713, 2009. e-Pub 2009.
117. Ahmed S, Bernasconi D, Crombie J, Frigault M, Hunter B, Kallam A, Kim S, Krimmel T, Liu FF, Pasquini M, Patel S, Roy D. Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) and Secondary CNS (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. TANDEM Meetings.
118. Ahmed S, DiPersio JF, Essell JH, Diefenbach CS, Perales MA, Castilla-Llorente C, Dahiya S, Chaudhry S, Xu H, Liu Y, Fanton C, Lee Z, Marcondes MQ, Tagliaferri M, Zalevsky J, Miklos DB, Turtle CJ, P McGuirk AJ. NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL). America Society of Hematology.
119. Ahmed S, Kallam A, Frigault M, Hunter BD, Patel SS, Bernasconi D, Kim S, Krimmel T, Liu FF, Roy D, Pasquini MC, L Crombie AJ. Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. American Society of Hematology.
120. Lee D, Thiruvengadam SK, Odstrcil Bobillo MS, Adedokun B, Shadman M, Olson AL, Herrera AF, Lee CJ, Jacobson CA, Bye M, Hamadani M, Kim S, Dahiya S, Hu Z, Speth K, To C, Mirjah DL, Best T, Locke FL, Ahmed N, Tees MT, Pasquini MC, Ahmed AS. Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). American Society of Hematology.
121. Lionel A, Gouni S, Feng L, Gaulin C, Gonugunta AS, Saridogan T, Abreu M, Varghese J, Ow K, Santiago M, Zaki AA, Adkins S, Ayers AA, Hawkins M, Kebriaei P, Shpall EJ, Iyer SP, Jain P, Wang M, Flowers CR, Ramdial J, Nastoupil L, Westin JR, Strati P, Neelapu SS, Chatterjee D, Ahmed AS. Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma. American Society of Hematology.
122. Riedell PA, Patel K, Dunleavy V, Karimi YH, Shah NN, Ribrag V, Ysebaert L, Noel R, Brisou G, Kline J, Bohac C, Naranjo C, Kanodia J, Woo J, Chen N, Michot J, Tessoulin B, Ahmed S. Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy. American Society of Hematology.
123. Gouni S, Lionel A, Feng L, Gaulin C, Reddy T, Gonugunta AS, Chu V, Hopper T, Ayers AA, Jackson I, Zaki AA, Hildebrandt MA, Nastoupil L, Chihara D, Nze C, Ramdial J, Shpall EJ, Westin JR, Flowers CR, Strati P, Neelapu SS, Lynn R, Ahmed AS. Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma. American Society of Hematology.
124. Gouni S, Lionel A, Feng L, Gaulin C, Reddy T, Gonugunta AS, Chu V, Hopper T, Ayers AA, Jackson I, Zaki AA, Hildebrandt MA, Nastoupil L, Chihara D, Nze C, Ramdial J, Shpall EJ, Westin JR, Flowers CR, Strati P, Neelapu SS, Lynn R, Ahmed AS. Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma. American Society of Hematology.
125. Isufi I, Ahmed S, Andreadis C, Bernasconi D, Crombie J, Frigault M, Kim S, Krimmel T, Lin Y, Mirza A, Pasquini M, Roy D, Toron F. Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso‑cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. TANDEM Meetings.
126. Gouni S, Ahmed S, Zaki AA, Ayers A, Chihara D, Chu V, Feng L, Flowers C, Gaulin C, Gonugunta A, Hildebrandt M, Hopper T, Jackson I, Lionel A, Lynn R, Nastoupil L, Neelapu S, Nze C, Ramdial J, Reddy T, Shpall E, Strati P, Westin J. Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma. TANDEM Meetings.
127. Rojek A, Ahmed S, Ahmed N, Bachanova V, Bishop M, Brower J, Chen A, Gomez-Llobell M, Hu M, Landsburg D, Maziarz R, McGuirk J, Mead M, Oluwole O, Patel V, Perales M, Porter D, Riedell P. CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium.

Book Chapters

1. Al-Juhaishi, T, Ahmed, S. Hematopoietic Cell Transplantation for Hodgkin Lymphoma. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies, 357-370, 2023.
2. Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.
3. Ahmed, S. Hematopoietic stem cell transplantation for hodgkin lymphoma, 231-243, 2019.
4. Ahmed, S, Champlin, RE. Indications for hematopoietic transplantation for aml, 777-797, 2015.
5. Ahmed, S, Qazilbash, MH. Chronic myeloid leukemia, 328-334, 2014.
6. Ahmed, S, Nieto, Y. Late Effects after Autologous Hematopoietic Stem Cell Transplantation, 31-42, 2013.

Letters to the Editor

1. Epperla, N, Hashmi, H, Ahn, KW, Allbee-Johnson, M, Chen, A, Wirk, B, Kanakry, JA, Lekakis, L, Kharfan-Dabaja, MA, Scordo, M, Riedell, PA, Jain, T, Shadman, M, Sauter, C, Hamadani, M, Herrera, AF, Ahmed, S. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy. British Journal of Haematology 205: 1202-1207, 2024.
2. Malek, A, Al-Juhaishi, T, Milton, D, Ramdial, JL, Daher, M, Olson, AL, Srour, S, Al-Atrash, G, Oran, B, Mehta, RS, Khouri, IF, Bashir, Q, Shah, N, Ciurea, SO, Rondon, G, Maadani, F, Hosing, C, Marin, D, Kebriaei, P, Rezvani, K, Nieto, Y, Anderlini, P, Alousi, AM, Faisal, MS, Qazilbash, MH, Popat, UR, Champlin, RE, Shpall, E, Mulanovich, VE, Ahmed, S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59: 699-704, 2024.
3. Mamlouk, O, Strati, P, Feng, L, Sun, R, Ayers, AA, Steiner, RE, Nair, R, Flowers, CR, Ramdial, JL, Saini, N, Srour, S, Champlin, RE, Kebriaei, P, Nastoupil, L, Rodriguez, MA, Shpall, E, Nieto, Y, Westin, JR, Neelapu, SS, Mandayam, S, Ahmed, S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. British Journal of Haematology 204: e11-e16, 2024.
4. Steiner, RE, Parra Cuentas, ER, Vega Vazquez, F, Feng, L, Westin, JR, Neelapu, SS, Strati, P, Green, M, Flowers, CR, Solis Soto, LM, Wistuba, II, Ahmed, S, Nair, R, Hagemeister, FB, Noorani, M, Marques-Piubelli, ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Experimental Hematology and Oncology 12, 2023.
5. Li, X, Henderson, J, Gordon, MJ, Sheikh, IN, Nastoupil, L, Westin, JR, Flowers, CR, Ahmed, S, Wang, L, Neelapu, SS, Strati, P, Deng, Q, Green, M. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer cell 41: 1835-1837, 2023.
6. Epperla, N, Feng, L, Shah, N, Fitzgerald, L, Shah, HR, Stephens, DM, Lee, CJ, Ollila, T, Shouse, G, Danilov, AV, David, K, Torka, P, Hashmi, H, Hess, B, Barta, S, Romancik, JT, Cohen, JB, Annunzio, K, Kittai, AS, Reneau, J, Zurko, J, Nizamuddin, I, Winter, JN, Gordon, LI, Ma, S, Patel, R, Nastoupil, L, Ahmed, S, Karmali, R. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. Journal of Hematology and Oncology 16: 111, 2023.
7. Jallouk, AP, Gouni, S, Westin, JR, Feng, L, Mistry, HE, Steiner, RE, James, J, Noorani, M, Horowitz, S, Puebla-Osorio, N, Fayad, LE, Iyer, SP, Hawkins, MC, Flowers, CR, Ahmed, S, Nastoupil, L, Kebriaei, P, Shpall, E, Neelapu, SS, Nieto, Y, Strati, P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108: 1163-1167, 2023.
8. Mamlouk, O, Nair, R, Iyer, SP, Edwards, AR, Neelapu, SS, Steiner, RE, Adkins, S, Hawkins, MC, Saini, N, Devashish, K, Strati, P, Mandayam, S, Ahmed, S. Safety of CAR T-cell therapy in kidney transplant recipients. Blood 137: 2558-2562, 2021.
9. Jain, P, Nastoupil, L, Westin, JR, Lee, HJ, Navsaria, L, Steiner, RE, Ahmed, S, Moghrabi, O, Oriabure, O, Chen, W, Badillo, M, Flowers, CR, Wang, L. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. British Journal of Haematology 192: e38-e42, 2021.
10. Strati, P, Ahmed, S, Kebriaei, P, Nastoupil, L, Claussen, C, Watson, G, Horowitz, S, Tanner, AR, Do, B, Rodriguez, MA, Nair, R, Shpall, E, Green, M, Neelapu, SS, Westin, JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma. Blood Advances 4: 3123-3127, 2020.
11. Saini, N, Patel, R, Varma, A, Bashir, Q, Delgado, R, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Patel, K, Orlowski, R, Champlin, RE, Qazilbash, MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. American journal of hematology 94: E2-E5, 2019.
12. Mehta, RS, Bassett Jr, R, Olson, AL, Chen, J, Ahmed, S, Alousi, AM, Anderlini, P, Al-Atrash, G, Bashir, Q, Ciurea, SO, Hosing, C, Im, JS, Kebriaei, P, Khouri, IF, Marin, D, Molldrem, JJ, Nieto, Y, Oran, B, Rezvani, K, Qazilbash, MH, Srour, S, Shpall, E, Andersson, BS, Champlin, RE, Popat, UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia. Haematologica 104: E555-E557, 2019.
13. Kongtim, P, Adekola, K, Milton, D, Ramlal, R, Jimenez, A, Chen, J, Rondon, G, Ahmed, S, Kebriaei, P, Oran, B, Hosing, C, Popat, UR, Khouri, IF, Jabbour, EJ, Cortes, JE, Kantarjian, HM, Champlin, RE, Ciurea, SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia 31: 1654-1657, 2017.
14. Varma, A, Saliba, RM, Torres, HA, Afrough, A, Hosing, C, Khouri, IF, Nieto, Y, Shah, ND, Parmar, S, Bashir, Q, Ahmed, S, Jones, R, Kebriaei, P, Olson, AL, Shpall, E, Alousi, AM, Qazilbash, MH, Champlin, RE, Popat, UR. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone marrow transplantation 51: 999-1001, 2016.
15. Lionel, AC, Gurumurthi, A, Fetooh, A, Eldaya, R, Ahmed, S, Iyer, SP, Nastoupil, L, Westin, JR, Nair, R, Fayad, LE, Malpica Castillo, LE, Tummala, S, Flowers, CR, Neelapu, SS, Wang, ML, Jain, P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leukemia and Lymphoma 65: 669-673.